Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8676222,peak plasma ATRA level,"After administration of ATRA at a dose of 30 mg/m2, the peak plasma ATRA level was 20-741 ng/ml and was reached at 60-120 min.",4-oxo retinoic acid for refractory acute promyelocytic leukemia in children with all-trans retinoic acid therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8676222/),[ng] / [ml],20-741,2068,DB00755,Tretinoin
,6104581,apparent volume of distribution,The apparent volume of distribution of HPR was approximately 10-12 liter/kg and the terminal half-life was 12 hr.,Pharmacokinetics of N-(4-hydroxyphenyl)-all-trans-retinamide in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6104581/),[l] / [kg],10-12,2689,DB00755,Tretinoin
,6104581,terminal half-life,The apparent volume of distribution of HPR was approximately 10-12 liter/kg and the terminal half-life was 12 hr.,Pharmacokinetics of N-(4-hydroxyphenyl)-all-trans-retinamide in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6104581/),h,12,2690,DB00755,Tretinoin
,1403674,elimination rate constant,"The mean elimination rate constant, calculated from data from iv administration, was 0.72 +/- 0.088 h-1 (r = 0.988).",Pharmacokinetics of parenteral 13-cis-retinoic acid formulations in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403674/),1/[h],0.72,2827,DB00755,Tretinoin
,1403674,peak concentration,"The peak concentration in plasma and the time to reach this maximum were 14 mg/L and 0.5 h, 22 mg/L and 2 h, and 10 mg/L and 1 h for the drug administered as an alkaline solution, suspended in corn oil, and as a mixture with polysorbate 80, respectively.",Pharmacokinetics of parenteral 13-cis-retinoic acid formulations in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403674/),[mg] / [l],14,2828,DB00755,Tretinoin
,1403674,peak concentration,"The peak concentration in plasma and the time to reach this maximum were 14 mg/L and 0.5 h, 22 mg/L and 2 h, and 10 mg/L and 1 h for the drug administered as an alkaline solution, suspended in corn oil, and as a mixture with polysorbate 80, respectively.",Pharmacokinetics of parenteral 13-cis-retinoic acid formulations in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403674/),h,0.5,2829,DB00755,Tretinoin
,1403674,peak concentration,"The peak concentration in plasma and the time to reach this maximum were 14 mg/L and 0.5 h, 22 mg/L and 2 h, and 10 mg/L and 1 h for the drug administered as an alkaline solution, suspended in corn oil, and as a mixture with polysorbate 80, respectively.",Pharmacokinetics of parenteral 13-cis-retinoic acid formulations in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403674/),[mg] / [l],22,2830,DB00755,Tretinoin
,1403674,peak concentration,"The peak concentration in plasma and the time to reach this maximum were 14 mg/L and 0.5 h, 22 mg/L and 2 h, and 10 mg/L and 1 h for the drug administered as an alkaline solution, suspended in corn oil, and as a mixture with polysorbate 80, respectively.",Pharmacokinetics of parenteral 13-cis-retinoic acid formulations in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403674/),h,2,2831,DB00755,Tretinoin
,1403674,peak concentration,"The peak concentration in plasma and the time to reach this maximum were 14 mg/L and 0.5 h, 22 mg/L and 2 h, and 10 mg/L and 1 h for the drug administered as an alkaline solution, suspended in corn oil, and as a mixture with polysorbate 80, respectively.",Pharmacokinetics of parenteral 13-cis-retinoic acid formulations in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403674/),[mg] / [l],10,2832,DB00755,Tretinoin
,1403674,time to reach this maximum,"The peak concentration in plasma and the time to reach this maximum were 14 mg/L and 0.5 h, 22 mg/L and 2 h, and 10 mg/L and 1 h for the drug administered as an alkaline solution, suspended in corn oil, and as a mixture with polysorbate 80, respectively.",Pharmacokinetics of parenteral 13-cis-retinoic acid formulations in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403674/),h,0.5,2833,DB00755,Tretinoin
,1403674,time to reach this maximum,"The peak concentration in plasma and the time to reach this maximum were 14 mg/L and 0.5 h, 22 mg/L and 2 h, and 10 mg/L and 1 h for the drug administered as an alkaline solution, suspended in corn oil, and as a mixture with polysorbate 80, respectively.",Pharmacokinetics of parenteral 13-cis-retinoic acid formulations in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403674/),[mg] / [l],10,2834,DB00755,Tretinoin
,1403674,time to reach this maximum,"The peak concentration in plasma and the time to reach this maximum were 14 mg/L and 0.5 h, 22 mg/L and 2 h, and 10 mg/L and 1 h for the drug administered as an alkaline solution, suspended in corn oil, and as a mixture with polysorbate 80, respectively.",Pharmacokinetics of parenteral 13-cis-retinoic acid formulations in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403674/),h,1,2835,DB00755,Tretinoin
,1403674,areas under the concentration-time curve (concentration in plasma versus time),"The areas under the concentration-time curve (concentration in plasma versus time) were 34.9 +/- 8.78 mg.h/L for the iv dose and 34.1 +/- 9.97, 62.4 +/- 32.3, and 25.9 +/- 12.0 mg.h/L for the ip doses of alkaline solution, suspension in oil, and mixture with polysorbate 80, respectively.",Pharmacokinetics of parenteral 13-cis-retinoic acid formulations in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403674/),[h·mg] / [l],34.9,2836,DB00755,Tretinoin
,1403674,areas under the concentration-time curve (concentration in plasma versus time),"The areas under the concentration-time curve (concentration in plasma versus time) were 34.9 +/- 8.78 mg.h/L for the iv dose and 34.1 +/- 9.97, 62.4 +/- 32.3, and 25.9 +/- 12.0 mg.h/L for the ip doses of alkaline solution, suspension in oil, and mixture with polysorbate 80, respectively.",Pharmacokinetics of parenteral 13-cis-retinoic acid formulations in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403674/),[h·mg] / [l],34.1,2837,DB00755,Tretinoin
,1403674,areas under the concentration-time curve (concentration in plasma versus time),"The areas under the concentration-time curve (concentration in plasma versus time) were 34.9 +/- 8.78 mg.h/L for the iv dose and 34.1 +/- 9.97, 62.4 +/- 32.3, and 25.9 +/- 12.0 mg.h/L for the ip doses of alkaline solution, suspension in oil, and mixture with polysorbate 80, respectively.",Pharmacokinetics of parenteral 13-cis-retinoic acid formulations in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403674/),[h·mg] / [l],62.4,2838,DB00755,Tretinoin
,1403674,areas under the concentration-time curve (concentration in plasma versus time),"The areas under the concentration-time curve (concentration in plasma versus time) were 34.9 +/- 8.78 mg.h/L for the iv dose and 34.1 +/- 9.97, 62.4 +/- 32.3, and 25.9 +/- 12.0 mg.h/L for the ip doses of alkaline solution, suspension in oil, and mixture with polysorbate 80, respectively.",Pharmacokinetics of parenteral 13-cis-retinoic acid formulations in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403674/),[h·mg] / [l],25.9,2839,DB00755,Tretinoin
,23909409,half-lives,"Thus, the mean half-lives of alitretinoin were 5·3 and 5·6 h (P = 0.733) and the oral clearances were 1·92 and 1·39 L h(-1) kg(-1) (P = 0·243) in the patient group and the healthy control group, respectively.",The single-dose pharmacokinetics of alitretinoin and its metabolites are not significantly altered in patients with cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23909409/),h,5·3,4409,DB00755,Tretinoin
,23909409,half-lives,"Thus, the mean half-lives of alitretinoin were 5·3 and 5·6 h (P = 0.733) and the oral clearances were 1·92 and 1·39 L h(-1) kg(-1) (P = 0·243) in the patient group and the healthy control group, respectively.",The single-dose pharmacokinetics of alitretinoin and its metabolites are not significantly altered in patients with cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23909409/),h,5·6,4410,DB00755,Tretinoin
,23909409,oral clearances,"Thus, the mean half-lives of alitretinoin were 5·3 and 5·6 h (P = 0.733) and the oral clearances were 1·92 and 1·39 L h(-1) kg(-1) (P = 0·243) in the patient group and the healthy control group, respectively.",The single-dose pharmacokinetics of alitretinoin and its metabolites are not significantly altered in patients with cirrhosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23909409/),[l] / [h·kg],1·92,4411,DB00755,Tretinoin
,23909409,oral clearances,"Thus, the mean half-lives of alitretinoin were 5·3 and 5·6 h (P = 0.733) and the oral clearances were 1·92 and 1·39 L h(-1) kg(-1) (P = 0·243) in the patient group and the healthy control group, respectively.",The single-dose pharmacokinetics of alitretinoin and its metabolites are not significantly altered in patients with cirrhosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23909409/),[l] / [h·kg],1·39,4412,DB00755,Tretinoin
,7715086,peak plasma level,The each peak plasma level of ATRA was 89 and 149 ng/ml.,[Induction and maintenance therapy in all-trans retinoic acid with relapsed acute promyelocytic leukemia]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715086/),[ng] / [ml],89,14707,DB00755,Tretinoin
,7715086,peak plasma level,The each peak plasma level of ATRA was 89 and 149 ng/ml.,[Induction and maintenance therapy in all-trans retinoic acid with relapsed acute promyelocytic leukemia]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715086/),[ng] / [ml],149,14708,DB00755,Tretinoin
,7120094,half-lives,"The half-lives for the terminal linear portion of the elimination phase after the plateau level were 0.78, 0.74, and 0.93 hr for the 1-, 2.5-, and 5-mg doses, respectively.",Blood level studies of all-trans- and 13-cis-retinoic acids in rats using different formulations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120094/),h,0.78,19063,DB00755,Tretinoin
,7120094,half-lives,"The half-lives for the terminal linear portion of the elimination phase after the plateau level were 0.78, 0.74, and 0.93 hr for the 1-, 2.5-, and 5-mg doses, respectively.",Blood level studies of all-trans- and 13-cis-retinoic acids in rats using different formulations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120094/),h,0.74,19064,DB00755,Tretinoin
,7120094,half-lives,"The half-lives for the terminal linear portion of the elimination phase after the plateau level were 0.78, 0.74, and 0.93 hr for the 1-, 2.5-, and 5-mg doses, respectively.",Blood level studies of all-trans- and 13-cis-retinoic acids in rats using different formulations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120094/),h,0.93,19065,DB00755,Tretinoin
,7120094,bioavailability,The bioavailability of all-trans-retinoic acid in oral solution was approximately 40% of the intravenous dose.,Blood level studies of all-trans- and 13-cis-retinoic acids in rats using different formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120094/),%,40,19066,DB00755,Tretinoin
,21443600,C(max),"Drug exposure was markedly increased when alitretinoin was taken with food compared with fasting, and there were significant increases in mean C(max) (82.8 vs.25.4 ng/mL, respectively) and AUC (220.2 vs. 55.7 ng · h/mL).",Influence of food on the pharmacokinetics of oral alitretinoin (9-cis retinoic acid). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21443600/),[ng] / [ml],82.8,20223,DB00755,Tretinoin
,21443600,C(max),"Drug exposure was markedly increased when alitretinoin was taken with food compared with fasting, and there were significant increases in mean C(max) (82.8 vs.25.4 ng/mL, respectively) and AUC (220.2 vs. 55.7 ng · h/mL).",Influence of food on the pharmacokinetics of oral alitretinoin (9-cis retinoic acid). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21443600/),[ng] / [ml],25.4,20224,DB00755,Tretinoin
,21443600,AUC,"Drug exposure was markedly increased when alitretinoin was taken with food compared with fasting, and there were significant increases in mean C(max) (82.8 vs.25.4 ng/mL, respectively) and AUC (220.2 vs. 55.7 ng · h/mL).",Influence of food on the pharmacokinetics of oral alitretinoin (9-cis retinoic acid). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21443600/),[h·ng] / [ml],220.2,20225,DB00755,Tretinoin
,21443600,AUC,"Drug exposure was markedly increased when alitretinoin was taken with food compared with fasting, and there were significant increases in mean C(max) (82.8 vs.25.4 ng/mL, respectively) and AUC (220.2 vs. 55.7 ng · h/mL).",Influence of food on the pharmacokinetics of oral alitretinoin (9-cis retinoic acid). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21443600/),[h·ng] / [ml],55.7,20226,DB00755,Tretinoin
,21443600,t(max),The delaying effect of food on t(max) was less marked (median of 3.0 vs. 2.0 h).,Influence of food on the pharmacokinetics of oral alitretinoin (9-cis retinoic acid). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21443600/),h,3.0,20227,DB00755,Tretinoin
,21443600,t(max),The delaying effect of food on t(max) was less marked (median of 3.0 vs. 2.0 h).,Influence of food on the pharmacokinetics of oral alitretinoin (9-cis retinoic acid). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21443600/),h,2.0,20228,DB00755,Tretinoin
,9423333,peak plasma concentration,"After oral administration at a dose of 30 mg/m2, the mean peak plasma concentration was 430 ng/ml and was reached at 150 min.",[Pharmacokinetic studies of all-trans retinoic acid (ATRA) and pilot study of intermittent schedule of ATRA and chemotherapy in childhood acute promyelocytic leukemia. Children's Cancer and Leukemia Study Group]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423333/),[ng] / [ml],430,20738,DB00755,Tretinoin
>,24726842,absolute oral bioavailability,Its absolute oral bioavailability was >100%.,VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726842/),%,100,20944,DB00755,Tretinoin
,7775262,time required to reach the peak plasma level,"After oral administration at a dose of 30 mg/m2, the time required to reach the peak plasma level of ATRA (20-1198 ng/ml) was between 120 and 240 min and the apparent plasma elimination half life was 21-51 min.",Pharmacokinetics of all-trans retinoic acid in pediatric patients with leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7775262/),[ng] / [ml],20-1198,24517,DB00755,Tretinoin
,7775262,time required to reach the peak plasma level,"After oral administration at a dose of 30 mg/m2, the time required to reach the peak plasma level of ATRA (20-1198 ng/ml) was between 120 and 240 min and the apparent plasma elimination half life was 21-51 min.",Pharmacokinetics of all-trans retinoic acid in pediatric patients with leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7775262/),min,120 and 240,24518,DB00755,Tretinoin
,7775262,apparent plasma elimination half life,"After oral administration at a dose of 30 mg/m2, the time required to reach the peak plasma level of ATRA (20-1198 ng/ml) was between 120 and 240 min and the apparent plasma elimination half life was 21-51 min.",Pharmacokinetics of all-trans retinoic acid in pediatric patients with leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7775262/),min,21-51,24519,DB00755,Tretinoin
,6144477,apparent bioavailability,"In addition, the apparent bioavailability of isotretinoin was 14% in bile cannulated dogs and 54% in the intact (uncannulated) animals, suggesting that enterohepatic recycling of isotretinoin may contribute to its oral bioavailability.",Effect of route of administration and biliary excretion on the pharmacokinetics of isotretinoin in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144477/),%,14,24595,DB00755,Tretinoin
,6144477,apparent bioavailability,"In addition, the apparent bioavailability of isotretinoin was 14% in bile cannulated dogs and 54% in the intact (uncannulated) animals, suggesting that enterohepatic recycling of isotretinoin may contribute to its oral bioavailability.",Effect of route of administration and biliary excretion on the pharmacokinetics of isotretinoin in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144477/),%,54,24596,DB00755,Tretinoin
,20660125,IC(50),"CCX282-B inhibited CCR9-mediated Ca(2+) mobilization and chemotaxis on Molt-4 cells with IC(50) values of 5.4 and 3.4 nM, respectively.","Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660125/),nM,5.4,26124,DB00755,Tretinoin
,20660125,IC(50),"CCX282-B inhibited CCR9-mediated Ca(2+) mobilization and chemotaxis on Molt-4 cells with IC(50) values of 5.4 and 3.4 nM, respectively.","Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660125/),nM,3.4,26125,DB00755,Tretinoin
,20660125,IC(50),"In the presence of 100% human serum, CCX282-B inhibited CCR9-mediated chemotaxis with an IC(50) of 33 nM, and the addition of α1-acid glycoprotein did not affect its potency.","Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660125/),nM,33,26126,DB00755,Tretinoin
,20660125,IC(50),CCX282-B inhibited chemotaxis of primary CCR9-expressing cells to CCL25 with an IC(50) of 6.8 nM.,"Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660125/),nM,6.8,26127,DB00755,Tretinoin
,20660125,IC(50),"CCX282-B was an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC(50) values of 2.8 and 2.6 nM, respectively.","Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660125/),nM,2.8,26128,DB00755,Tretinoin
,20660125,IC(50),"CCX282-B was an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC(50) values of 2.8 and 2.6 nM, respectively.","Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660125/),nM,2.6,26129,DB00755,Tretinoin
,10367173,ratio of the area under the curve,The ratio of the area under the curve for the 4-oxo metabolite relative to that of the parent compound increased from less than 1 on day 1 to approximately 2.4 on days 8 and 28.,Preliminary phase II clinical and pharmacokinetic study of 9-cis retinoic acid in advanced cervical cancer. New York Gynecologic Oncology Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367173/),,1,26719,DB00755,Tretinoin
,8149876,Elimination half-life,"Elimination half-life was longer for the cis-compounds and not dose-dependent (N = 1 for 13-cis-4-oxo RA, N = 3 for other compounds, harmonic mean +/- pseudostandard deviation, min): 13-cis-4-oxo RA (837) > or = 13-cis-RA (301 +/- 204) > all-trans-RA (38 +/- 3) > all-trans-4-oxo RA (11 +/- 2).","Pharmacokinetics of 13-cis-, all-trans-, 13-cis-4-oxo-, and all-trans-4-oxo retinoic acid after intravenous administration in the cynomolgus monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149876/),,837,29614,DB00755,Tretinoin
,8149876,Elimination half-life,"Elimination half-life was longer for the cis-compounds and not dose-dependent (N = 1 for 13-cis-4-oxo RA, N = 3 for other compounds, harmonic mean +/- pseudostandard deviation, min): 13-cis-4-oxo RA (837) > or = 13-cis-RA (301 +/- 204) > all-trans-RA (38 +/- 3) > all-trans-4-oxo RA (11 +/- 2).","Pharmacokinetics of 13-cis-, all-trans-, 13-cis-4-oxo-, and all-trans-4-oxo retinoic acid after intravenous administration in the cynomolgus monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149876/),,301,29615,DB00755,Tretinoin
,8149876,Elimination half-life,"Elimination half-life was longer for the cis-compounds and not dose-dependent (N = 1 for 13-cis-4-oxo RA, N = 3 for other compounds, harmonic mean +/- pseudostandard deviation, min): 13-cis-4-oxo RA (837) > or = 13-cis-RA (301 +/- 204) > all-trans-RA (38 +/- 3) > all-trans-4-oxo RA (11 +/- 2).","Pharmacokinetics of 13-cis-, all-trans-, 13-cis-4-oxo-, and all-trans-4-oxo retinoic acid after intravenous administration in the cynomolgus monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149876/),,38,29616,DB00755,Tretinoin
,8149876,Elimination half-life,"Elimination half-life was longer for the cis-compounds and not dose-dependent (N = 1 for 13-cis-4-oxo RA, N = 3 for other compounds, harmonic mean +/- pseudostandard deviation, min): 13-cis-4-oxo RA (837) > or = 13-cis-RA (301 +/- 204) > all-trans-RA (38 +/- 3) > all-trans-4-oxo RA (11 +/- 2).","Pharmacokinetics of 13-cis-, all-trans-, 13-cis-4-oxo-, and all-trans-4-oxo retinoic acid after intravenous administration in the cynomolgus monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149876/),,11,29617,DB00755,Tretinoin
,6461675,apparent half-lives of elimination,"The apparent half-lives of elimination of isotretinoin and 4-oxo-isotretinoin following the oral administration of isotretinoin range from 10 to 20 hours and 24 to 29 hours, respectively.",Pharmacokinetics of the retinoids isotretinoin and etretinate. A comparative review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6461675/),h,10 to 20,33439,DB00755,Tretinoin
,6461675,apparent half-lives of elimination,"The apparent half-lives of elimination of isotretinoin and 4-oxo-isotretinoin following the oral administration of isotretinoin range from 10 to 20 hours and 24 to 29 hours, respectively.",Pharmacokinetics of the retinoids isotretinoin and etretinate. A comparative review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6461675/),h,24 to 29,33440,DB00755,Tretinoin
,6461675,apparent elimination rates,"The apparent elimination rates of drug and metabolite are similar (6-13 hours) following a single dose, suggesting that metabolite elimination may be formation-rate limited.",Pharmacokinetics of the retinoids isotretinoin and etretinate. A comparative review. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6461675/),h,6-13,33441,DB00755,Tretinoin
,1559217,Peak plasma levels,"Peak plasma levels of all-trans RA (347 +/- 266 ng/ml, mean +/- SD) were reached 1-2 h after drug ingestion and decayed in a monoexponential fashion with a half-life of 0.8 +/- 0.1 h.",Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559217/),[ng] / [ml],347,34697,DB00755,Tretinoin
,1559217,half-life,"Peak plasma levels of all-trans RA (347 +/- 266 ng/ml, mean +/- SD) were reached 1-2 h after drug ingestion and decayed in a monoexponential fashion with a half-life of 0.8 +/- 0.1 h.",Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559217/),h,0.8,34698,DB00755,Tretinoin
below,2976002,Residual plasma concentrations,Residual plasma concentrations of Ro 13-7652 were below the quantification limit in 7 cases and respectively of 3 and 4 ng/ml in the other 2 cases.,Residual plasma concentrations of acitretin (Ro 10-1670) and its metabolite (Ro 13-7652) after chronic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2976002/),[ng] / [ml],3,35137,DB00755,Tretinoin
,2976002,Residual plasma concentrations,Residual plasma concentrations of Ro 13-7652 were below the quantification limit in 7 cases and respectively of 3 and 4 ng/ml in the other 2 cases.,Residual plasma concentrations of acitretin (Ro 10-1670) and its metabolite (Ro 13-7652) after chronic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2976002/),[ng] / [ml],4,35138,DB00755,Tretinoin
,7595702,C,"Comparison of ATRA intracellular levels with the in vitro response of patients' cell samples as measured by the percentage of nitro blue tetrazolium (NBT)-positive cells after a 3-day incubation period allowed us to discriminate a group of APL patients (n = 6) with high Cmax (group A; median, 200 pmol/10(6) cells) and maximal differentiation at day 3 (median, 80%), and a group of patients (n = 8, three APL and five non-APL) with low Cmax (group B; median, 35 pmol/10(6) cells) and poor in vitro response (median, 40%; APL cases only).",All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595702/),,35,37058,DB00755,Tretinoin
,7808020,maximum tolerated dose (MTD),"We previously performed a standard pediatric phase I trial of ATRA and defined the maximum tolerated dose (MTD) in children to be 60 mg/m2/day, significantly lower than the MTD in adult patients.",Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7808020/),[mg] / [d·m2],60,45888,DB00755,Tretinoin
,7808020,plasma half-life,"Pharmacokinetic results revealed that the plasma half-life of ATRA was short (45 min) relative to 13-cis-RA (12-24 h), and that plasma drug exposure decreased significantly by day 28 of daily drug administration.",Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7808020/),min,45,45889,DB00755,Tretinoin
,7808020,plasma half-life,"Pharmacokinetic results revealed that the plasma half-life of ATRA was short (45 min) relative to 13-cis-RA (12-24 h), and that plasma drug exposure decreased significantly by day 28 of daily drug administration.",Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7808020/),h,12-24,45890,DB00755,Tretinoin
,8611689,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) was determined to be 140 mg/m2, at which dose grade 2 toxicity (primarily headache and skin) occurred in eight of eight patients, but grade 3 to 4 toxicity in none.",Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611689/),mg,140,46633,DB00755,Tretinoin
,2575501,systemic clearance,"The systemic clearance of etretinate was significantly lower in the pregnant rats compared to nonpregnant controls (129 vs. 185 ml/hr, respectively; p less than 0.05).",Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. I. Intravenous studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575501/),[ml] / [h],129,47294,DB00755,Tretinoin
,2575501,systemic clearance,"The systemic clearance of etretinate was significantly lower in the pregnant rats compared to nonpregnant controls (129 vs. 185 ml/hr, respectively; p less than 0.05).",Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. I. Intravenous studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575501/),[ml] / [h],185,47295,DB00755,Tretinoin
,2575501,formation clearance,This decrease was entirely due to a lower formation clearance of acitretin (acid) from etretinate (ester) in the pregnant animals (96 vs. 146 ml/hr; p less than 0.05).,Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. I. Intravenous studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575501/),[ml] / [h],96,47296,DB00755,Tretinoin
,2575501,formation clearance,This decrease was entirely due to a lower formation clearance of acitretin (acid) from etretinate (ester) in the pregnant animals (96 vs. 146 ml/hr; p less than 0.05).,Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. I. Intravenous studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575501/),[ml] / [h],146,47297,DB00755,Tretinoin
,2575501,systemic clearance,"By contrast, the systemic clearance of acitretin was greater in the pregnant compared to the nonpregnant control animals (184 vs. 145 ml/hr, respectively; p less than 0.05).",Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. I. Intravenous studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575501/),[ml] / [h],184,47298,DB00755,Tretinoin
,2575501,systemic clearance,"By contrast, the systemic clearance of acitretin was greater in the pregnant compared to the nonpregnant control animals (184 vs. 145 ml/hr, respectively; p less than 0.05).",Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. I. Intravenous studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575501/),[ml] / [h],145,47299,DB00755,Tretinoin
,2575501,systemic clearances,Etretinate infusions in nonpregnant animals yielded systemic clearances (mean = 164 ml/hr) which were similar to those obtained for bolus dose experiments.,Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. I. Intravenous studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575501/),[ml] / [h],164,47300,DB00755,Tretinoin
,22580781,half-life,PK results showed that VN/12-1 has a half-life of 6 h.,"Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22580781/),h,6,47431,DB00755,Tretinoin
,22580781,area under the curve (AUC),The area under the curve (AUC) for VN/12-1 was 83.78 h μg/ml.,"Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22580781/),[h·μg] / [ml],83.78,47432,DB00755,Tretinoin
,27701038,flow rate,"Chromatographic separation of the three analytes and N-(4-ethoxyphenyl)retinamide (4-EPR), an internal standard, was achieved on a Zorbax SB-C18 column (3.5μm, 50×2.1mm) using gradient elution with the mobile phase of 0.1% formic acid in water and acetonitrile (pH* 2.4) at a flow rate of 0.5mL/min.",Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27701038/),[ml] / [min],0.5,47590,DB00755,Tretinoin
higher,27701038,extraction recoveries,The extraction recoveries were found to be higher than 90.39% and no matrix effect was observed.,Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27701038/),%,90.39,47591,DB00755,Tretinoin
<,18094222,C(max),"In contrast, administration of 13-cRA produced lower plasma ATRA C(max) (<100 ng/mL), but the levels were significantly higher at follow-up than those on day 1 (P < .001).",Pharmacokinetics and metabolism of all-trans- and 13-cis-retinoic acid in pulmonary emphysema patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094222/),[ng] / [ml],100,52279,DB00755,Tretinoin
,3856478,lag time,"An average lag time of 1.2 hours was observed, followed by fast absorption, with a mean half-life of 0.5 hour.",Single-dose pharmacokinetic study of 13-cis-retinoic acid in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3856478/),h,1.2,54210,DB00755,Tretinoin
,3856478,half-life,"An average lag time of 1.2 hours was observed, followed by fast absorption, with a mean half-life of 0.5 hour.",Single-dose pharmacokinetic study of 13-cis-retinoic acid in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3856478/),h,0.5,54211,DB00755,Tretinoin
,3856478,Peak plasmatic concentration,Peak plasmatic concentration of 733 ng/ml occurred at 2.3 hours.,Single-dose pharmacokinetic study of 13-cis-retinoic acid in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3856478/),[ng] / [ml],733,54212,DB00755,Tretinoin
,3856478,distribution half-life,The disposition profile showed a rapid distribution half-life of 1.3 hours and a terminal elimination half-life of 24.7 hours.,Single-dose pharmacokinetic study of 13-cis-retinoic acid in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3856478/),h,1.3,54213,DB00755,Tretinoin
,3856478,terminal elimination half-life,The disposition profile showed a rapid distribution half-life of 1.3 hours and a terminal elimination half-life of 24.7 hours.,Single-dose pharmacokinetic study of 13-cis-retinoic acid in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3856478/),h,24.7,54214,DB00755,Tretinoin
<,7808019,half-lives,RA is much more rapidly cleared from plasma following oral administration; their respective half-lives are < 1 h and 13 h.,Clinical pharmacology of all-trans retinoic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7808019/),h,1,54541,DB00755,Tretinoin
,7808019,half-lives,RA is much more rapidly cleared from plasma following oral administration; their respective half-lives are < 1 h and 13 h.,Clinical pharmacology of all-trans retinoic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7808019/),h,13,54542,DB00755,Tretinoin
,12652617,Peak plasma concentrations,Peak plasma concentrations of ATRA were characterized by wide interpatient variability (range: 28.6-513.0 nM).,Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12652617/),nM,28.6-513.0,54858,DB00755,Tretinoin
,16651738,total concentration,"The total concentration of As(III), MMAs(V) and DMAs(V) in serum ranged from 18 to 41 microg/l (240-547 nM) during 24 h on Day 4.",Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16651738/),[μg] / [l],18 to 41,55583,DB00755,Tretinoin
,2521335,t beta 1/2,"Initial estimates of plasma pharmacokinetic parameters after oral administration of 4HPR (300 mg/day) [corrected] in 3 cancer patients were the following: 4HPR, t beta 1/2 = 13.7 hr, AUC = 3.49 micrograms.hr/ml, CL = 56.57 L/hr/m2; 4MPR, t beta 1/2 = 23.0 hr, AUC = 1.15 micrograms.hr/ml, CL = 239.29 L/hr/m2.",Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521335/),h,13.7,55910,DB00755,Tretinoin
,2521335,AUC,"Initial estimates of plasma pharmacokinetic parameters after oral administration of 4HPR (300 mg/day) [corrected] in 3 cancer patients were the following: 4HPR, t beta 1/2 = 13.7 hr, AUC = 3.49 micrograms.hr/ml, CL = 56.57 L/hr/m2; 4MPR, t beta 1/2 = 23.0 hr, AUC = 1.15 micrograms.hr/ml, CL = 239.29 L/hr/m2.",Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521335/),[h·μg] / [ml],3.49,55911,DB00755,Tretinoin
,2521335,CL,"Initial estimates of plasma pharmacokinetic parameters after oral administration of 4HPR (300 mg/day) [corrected] in 3 cancer patients were the following: 4HPR, t beta 1/2 = 13.7 hr, AUC = 3.49 micrograms.hr/ml, CL = 56.57 L/hr/m2; 4MPR, t beta 1/2 = 23.0 hr, AUC = 1.15 micrograms.hr/ml, CL = 239.29 L/hr/m2.",Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521335/),[l] / [h·m2],56.57,55912,DB00755,Tretinoin
,2521335,t beta 1/2,"Initial estimates of plasma pharmacokinetic parameters after oral administration of 4HPR (300 mg/day) [corrected] in 3 cancer patients were the following: 4HPR, t beta 1/2 = 13.7 hr, AUC = 3.49 micrograms.hr/ml, CL = 56.57 L/hr/m2; 4MPR, t beta 1/2 = 23.0 hr, AUC = 1.15 micrograms.hr/ml, CL = 239.29 L/hr/m2.",Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521335/),h,23.0,55913,DB00755,Tretinoin
,2521335,AUC,"Initial estimates of plasma pharmacokinetic parameters after oral administration of 4HPR (300 mg/day) [corrected] in 3 cancer patients were the following: 4HPR, t beta 1/2 = 13.7 hr, AUC = 3.49 micrograms.hr/ml, CL = 56.57 L/hr/m2; 4MPR, t beta 1/2 = 23.0 hr, AUC = 1.15 micrograms.hr/ml, CL = 239.29 L/hr/m2.",Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521335/),[h·μg] / [ml],1.15,55914,DB00755,Tretinoin
,2521335,CL,"Initial estimates of plasma pharmacokinetic parameters after oral administration of 4HPR (300 mg/day) [corrected] in 3 cancer patients were the following: 4HPR, t beta 1/2 = 13.7 hr, AUC = 3.49 micrograms.hr/ml, CL = 56.57 L/hr/m2; 4MPR, t beta 1/2 = 23.0 hr, AUC = 1.15 micrograms.hr/ml, CL = 239.29 L/hr/m2.",Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521335/),[l] / [h·m2],239.29,55915,DB00755,Tretinoin
,33115399,solubility,"Rod-shaped ATRA-SLNs could successfully incorporate 3.7 mg/mL of ATRA, increasing its solubility (from 4.7 μg/mL) by 787 times, having an average particle size of 131.30 ± 5.0 nm and polydispersibility of 0.283.",Enhanced Oral Absorption of All-trans Retinoic Acid upon Encapsulation in Solid Lipid Nanoparticles. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33115399/),[μg] / [ml],4.7,55917,DB00755,Tretinoin
,33115399,polydispersibility,"Rod-shaped ATRA-SLNs could successfully incorporate 3.7 mg/mL of ATRA, increasing its solubility (from 4.7 μg/mL) by 787 times, having an average particle size of 131.30 ± 5.0 nm and polydispersibility of 0.283.",Enhanced Oral Absorption of All-trans Retinoic Acid upon Encapsulation in Solid Lipid Nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33115399/),,0.283,55918,DB00755,Tretinoin
,33115399,total drug content,"Assay/total drug content and entrapment efficiency of ATRA-SLNs was 92.50 ± 2.10% and 84.60 ± 3.20% (n=6), respectively, which was maintained even on storage for one year under refrigerated conditions as an aqueous dispersion.",Enhanced Oral Absorption of All-trans Retinoic Acid upon Encapsulation in Solid Lipid Nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33115399/),%,92.50,55919,DB00755,Tretinoin
,33115399,entrapment efficiency,"Assay/total drug content and entrapment efficiency of ATRA-SLNs was 92.50 ± 2.10% and 84.60 ± 3.20% (n=6), respectively, which was maintained even on storage for one year under refrigerated conditions as an aqueous dispersion.",Enhanced Oral Absorption of All-trans Retinoic Acid upon Encapsulation in Solid Lipid Nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33115399/),%,84.60,55920,DB00755,Tretinoin
,25675244,critical micelle concentration (CMC),It can self-assemble into core-shell micelles with a low critical micelle concentration (CMC) at 3.48 mg/L.,Linear-dendritic copolymer composed of polyethylene glycol and all-trans-retinoic acid as drug delivery platform for paclitaxel against breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25675244/),[mg] / [l],3.48,58095,DB00755,Tretinoin
,25675244,area under the plasma concentration-time curve (AUC0-∞),"Pharmacokinetics and biodistribution studies (10 mg/kg) showed the area under the plasma concentration-time curve (AUC0-∞) and mean residence time (MRT0-∞) for PEG-G3-RA8/PTX and Taxol were 12.006 ± 0.605 mg/L h, 2.264 ± 0.041 h and 15.966 ± 1.614 mg/L h, 1.726 ± 0.097 h, respectively.",Linear-dendritic copolymer composed of polyethylene glycol and all-trans-retinoic acid as drug delivery platform for paclitaxel against breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25675244/),[mg] / [h·l],12.006,58096,DB00755,Tretinoin
,25675244,mean residence time (MRT0-∞),"Pharmacokinetics and biodistribution studies (10 mg/kg) showed the area under the plasma concentration-time curve (AUC0-∞) and mean residence time (MRT0-∞) for PEG-G3-RA8/PTX and Taxol were 12.006 ± 0.605 mg/L h, 2.264 ± 0.041 h and 15.966 ± 1.614 mg/L h, 1.726 ± 0.097 h, respectively.",Linear-dendritic copolymer composed of polyethylene glycol and all-trans-retinoic acid as drug delivery platform for paclitaxel against breast cancer. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25675244/),h,2.264,58097,DB00755,Tretinoin
,25675244,mean residence time (MRT0-∞),"Pharmacokinetics and biodistribution studies (10 mg/kg) showed the area under the plasma concentration-time curve (AUC0-∞) and mean residence time (MRT0-∞) for PEG-G3-RA8/PTX and Taxol were 12.006 ± 0.605 mg/L h, 2.264 ± 0.041 h and 15.966 ± 1.614 mg/L h, 1.726 ± 0.097 h, respectively.",Linear-dendritic copolymer composed of polyethylene glycol and all-trans-retinoic acid as drug delivery platform for paclitaxel against breast cancer. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25675244/),h,1.726,58098,DB00755,Tretinoin
,10701701,percutaneous absorption,Mean percutaneous absorption of [3H]tretinoin based on the cumulative recoveries of radioactivity in the urine and faeces was about 4.5% (median 2.18%).,Percutaneous absorption of [3H]tretinoin and systemic exposure to mequinol after dermal application of 2% mequinol/0.01% [3H]tretinoin (Solagé) solution in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701701/),%,4.5,62171,DB00755,Tretinoin
,10701701,percutaneous absorption,Mean percutaneous absorption of [3H]tretinoin based on the cumulative recoveries of radioactivity in the urine and faeces was about 4.5% (median 2.18%).,Percutaneous absorption of [3H]tretinoin and systemic exposure to mequinol after dermal application of 2% mequinol/0.01% [3H]tretinoin (Solagé) solution in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701701/),%,2.18,62172,DB00755,Tretinoin
,10701701,Cmax,"This was consistent with the concentrations of radioactivity in plasma, which showed an average Cmax of 91 pg-eq/mL (median 26 ng/mL).",Percutaneous absorption of [3H]tretinoin and systemic exposure to mequinol after dermal application of 2% mequinol/0.01% [3H]tretinoin (Solagé) solution in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701701/),[pg-eq] / [ml],91,62173,DB00755,Tretinoin
,10701701,Cmax,"This was consistent with the concentrations of radioactivity in plasma, which showed an average Cmax of 91 pg-eq/mL (median 26 ng/mL).",Percutaneous absorption of [3H]tretinoin and systemic exposure to mequinol after dermal application of 2% mequinol/0.01% [3H]tretinoin (Solagé) solution in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701701/),[ng] / [ml],26,62174,DB00755,Tretinoin
,10701701,Cmax,"Average Cmax and AUC(0-12 h) values for mequinol were 10 ng/mL and 33 ng h/mL, respectively.",Percutaneous absorption of [3H]tretinoin and systemic exposure to mequinol after dermal application of 2% mequinol/0.01% [3H]tretinoin (Solagé) solution in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701701/),[ng] / [ml],10,62175,DB00755,Tretinoin
,10701701,AUC(0-12 h),"Average Cmax and AUC(0-12 h) values for mequinol were 10 ng/mL and 33 ng h/mL, respectively.",Percutaneous absorption of [3H]tretinoin and systemic exposure to mequinol after dermal application of 2% mequinol/0.01% [3H]tretinoin (Solagé) solution in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701701/),[h·ng] / [ml],33,62176,DB00755,Tretinoin
,1403049,maximum-tolerated dose (MTD),The maximum-tolerated dose (MTD) of RA was 60 mg/m2/d.,Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403049/),[mg] / [d·m2],60,63850,DB00755,Tretinoin
,1403049,terminal half-life,"Pharmacokinetic studies demonstrated a relatively short terminal half-life for RA (45 minutes), with diminution in plasma levels after chronic dosing.",Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403049/),min,45,63851,DB00755,Tretinoin
higher,2763297,embryo/maternal plasma ratios,"At 8 hr, embryo/maternal plasma ratios were higher than 1 after administration of the all-trans compounds.","Teratogenicity and placental transfer of all-trans-, 13-cis-, 4-oxo-all-trans-, and 4-oxo-13-cis-retinoic acid after administration of a low oral dose during organogenesis in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2763297/),,1,78117,DB00755,Tretinoin
,9150861,Cmax,"After a single oral administration of 2 mg/kg, Cmax and AUC for tretinoin in rat plasma were 285 +/- 14.6 ng/ml and 595 +/- 123 ng h/ml, respectively.",Absorption of tretinoin in rats and rabbits following oral and dermal application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9150861/),[ng] / [ml],285,78328,DB00755,Tretinoin
,9150861,AUC,"After a single oral administration of 2 mg/kg, Cmax and AUC for tretinoin in rat plasma were 285 +/- 14.6 ng/ml and 595 +/- 123 ng h/ml, respectively.",Absorption of tretinoin in rats and rabbits following oral and dermal application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9150861/),[h·ng] / [ml],595,78329,DB00755,Tretinoin
,11595692,terminal half-life,"Peak plasma concentrations of 9cRA occurred at a median of 1.5 h after a p.o. dose, and the harmonic-mean terminal half-life was 43 min.","A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11595692/),min,43,79560,DB00755,Tretinoin
,8260694,time to CR,Median time to CR was 45 days.,Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8260694/),d,45,80107,DB00755,Tretinoin
,6957421,Maximum blood concentrations,Maximum blood concentrations of isotretinoin ranged from 74 to 511 ng/ml and occurred between 1 and 4 hours after dosing.,Pharmacokinetics of isotretinoin following a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6957421/),[ng] / [ml],74 to 511,81219,DB00755,Tretinoin
,6957421,elimination half-life,The harmonic mean elimination half-life was approximately 20 hours.,Pharmacokinetics of isotretinoin following a single oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6957421/),h,20,81220,DB00755,Tretinoin
,11052629,pulmonary half-life,"Aerosolization and IT injection of all-trans-RA resulted in a significantly longer pulmonary half-life of the drug (both 5-17 h), lower peak serum concentrations (aerosol 71 +/- 31 ng/ml, IT 68 +/- 50 ng/ml), and lower liver levels (aerosol 111 +/- 28 ng/g, IT 753 +/- 350 ng/g) than the same dose administered IV (2 h, 838 +/- 56 ng/ml, 4,258 +/- 1,006 ng/g, respectively; P < 0.05 for each comparison).",Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11052629/),h,5-17,82305,DB00755,Tretinoin
,11052629,peak serum concentrations,"Aerosolization and IT injection of all-trans-RA resulted in a significantly longer pulmonary half-life of the drug (both 5-17 h), lower peak serum concentrations (aerosol 71 +/- 31 ng/ml, IT 68 +/- 50 ng/ml), and lower liver levels (aerosol 111 +/- 28 ng/g, IT 753 +/- 350 ng/g) than the same dose administered IV (2 h, 838 +/- 56 ng/ml, 4,258 +/- 1,006 ng/g, respectively; P < 0.05 for each comparison).",Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11052629/),[ng] / [ml],71,82306,DB00755,Tretinoin
,11052629,peak serum concentrations,"Aerosolization and IT injection of all-trans-RA resulted in a significantly longer pulmonary half-life of the drug (both 5-17 h), lower peak serum concentrations (aerosol 71 +/- 31 ng/ml, IT 68 +/- 50 ng/ml), and lower liver levels (aerosol 111 +/- 28 ng/g, IT 753 +/- 350 ng/g) than the same dose administered IV (2 h, 838 +/- 56 ng/ml, 4,258 +/- 1,006 ng/g, respectively; P < 0.05 for each comparison).",Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11052629/),[ng] / [ml],68,82307,DB00755,Tretinoin
,11052629,liver levels,"Aerosolization and IT injection of all-trans-RA resulted in a significantly longer pulmonary half-life of the drug (both 5-17 h), lower peak serum concentrations (aerosol 71 +/- 31 ng/ml, IT 68 +/- 50 ng/ml), and lower liver levels (aerosol 111 +/- 28 ng/g, IT 753 +/- 350 ng/g) than the same dose administered IV (2 h, 838 +/- 56 ng/ml, 4,258 +/- 1,006 ng/g, respectively; P < 0.05 for each comparison).",Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11052629/),[ng] / [g],111,82308,DB00755,Tretinoin
,11052629,liver levels,"Aerosolization and IT injection of all-trans-RA resulted in a significantly longer pulmonary half-life of the drug (both 5-17 h), lower peak serum concentrations (aerosol 71 +/- 31 ng/ml, IT 68 +/- 50 ng/ml), and lower liver levels (aerosol 111 +/- 28 ng/g, IT 753 +/- 350 ng/g) than the same dose administered IV (2 h, 838 +/- 56 ng/ml, 4,258 +/- 1,006 ng/g, respectively; P < 0.05 for each comparison).",Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11052629/),[ng] / [g],753,82309,DB00755,Tretinoin
,11052629,liver levels,"Aerosolization and IT injection of all-trans-RA resulted in a significantly longer pulmonary half-life of the drug (both 5-17 h), lower peak serum concentrations (aerosol 71 +/- 31 ng/ml, IT 68 +/- 50 ng/ml), and lower liver levels (aerosol 111 +/- 28 ng/g, IT 753 +/- 350 ng/g) than the same dose administered IV (2 h, 838 +/- 56 ng/ml, 4,258 +/- 1,006 ng/g, respectively; P < 0.05 for each comparison).",Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11052629/),[ng] / [ml],838,82310,DB00755,Tretinoin
,11052629,liver levels,"Aerosolization and IT injection of all-trans-RA resulted in a significantly longer pulmonary half-life of the drug (both 5-17 h), lower peak serum concentrations (aerosol 71 +/- 31 ng/ml, IT 68 +/- 50 ng/ml), and lower liver levels (aerosol 111 +/- 28 ng/g, IT 753 +/- 350 ng/g) than the same dose administered IV (2 h, 838 +/- 56 ng/ml, 4,258 +/- 1,006 ng/g, respectively; P < 0.05 for each comparison).",Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11052629/),[ng] / [g],"4,258",82311,DB00755,Tretinoin
,1352212,half-life,"Etretinate, a highly lipophilic retinoid, is known to accumulate in the human body with a slow systemic elimination (half-life approximately 100 days) after long-term treatment.","Systemic pharmacokinetics of acitretin, etretinate, isotretinoin, and acetylenic retinoids in guinea pigs and obese rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352212/),d,100,83804,DB00755,Tretinoin
,2861992,apparent half-life,"The harmonic mean apparent half-life for isotretinoin in the blood of the healthy subjects was 13.6 hr, whereas the corresponding value for the 14C was 90 hr.",Pharmacokinetics of 14C-isotretinoin in healthy volunteers and volunteers with biliary T-tube drainage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861992/),h,13.6,89012,DB00755,Tretinoin
,2861992,apparent half-life,"The harmonic mean apparent half-life for isotretinoin in the blood of the healthy subjects was 13.6 hr, whereas the corresponding value for the 14C was 90 hr.",Pharmacokinetics of 14C-isotretinoin in healthy volunteers and volunteers with biliary T-tube drainage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861992/),h,90,89013,DB00755,Tretinoin
,16700821,Peak serum levels,Peak serum levels of 563 to 1640 ng/ml were observed for rats treated with 13-cis-retinoic acid at 1.5-2 hr after gavage.,Steady state pharmacokinetics of oral treatment with 13-cis-retinoic acid or all-trans-retinoic acid in male and female adult rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16700821/),[ng] / [ml],563 to 1640,89649,DB00755,Tretinoin
,16700821,Peak serum levels,Peak serum levels of 183 to 267 ng/ml at 1.5 hr after gavage were observed for all-trans-retinoic acids.,Steady state pharmacokinetics of oral treatment with 13-cis-retinoic acid or all-trans-retinoic acid in male and female adult rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16700821/),[ng] / [ml],183 to 267,89650,DB00755,Tretinoin
,16700821,elimination half-life,The elimination half-life of 13-cis-retinoic acid was about 1.5 hr while the elimination half-life of all-trans-retinoic acid was slightly longer.,Steady state pharmacokinetics of oral treatment with 13-cis-retinoic acid or all-trans-retinoic acid in male and female adult rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16700821/),h,1.5,89651,DB00755,Tretinoin
,6575916,half-lives,"Following rapid absorption from the suspension formulation, isotretinoin is distributed and eliminated with harmonic mean half-lives of 1.3 and 17.4 h, respectively.",Pharmacokinetics of isotretinoin and its major blood metabolite following a single oral dose to man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6575916/),h,1.3,91309,DB00755,Tretinoin
,6575916,half-lives,"Following rapid absorption from the suspension formulation, isotretinoin is distributed and eliminated with harmonic mean half-lives of 1.3 and 17.4 h, respectively.",Pharmacokinetics of isotretinoin and its major blood metabolite following a single oral dose to man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6575916/),h,17.4,91310,DB00755,Tretinoin
,6575916,steady-state ratios,The ratio of areas under the curve for metabolite and parent drug following the single dose suggests that average steady-state ratios of metabolite to parent drug during a dosing interval will be approximately 2.5.,Pharmacokinetics of isotretinoin and its major blood metabolite following a single oral dose to man. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6575916/),,2.5,91311,DB00755,Tretinoin
,2139274,peak plasma concentration levels (Cmax),Group A (n = 8) showed median peak plasma concentration levels (Cmax) 578 ng/ml for E. and 161 ng/ml for A 4h after dosing (tmax).,"[Pharmacokinetics of etretinate, acitretin and 13-cis-acitretin: new results and advantages of blood level oriented clinical use]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139274/),[ng] / [ml],578,92656,DB00755,Tretinoin
,2139274,peak plasma concentration levels (Cmax),Group A (n = 8) showed median peak plasma concentration levels (Cmax) 578 ng/ml for E. and 161 ng/ml for A 4h after dosing (tmax).,"[Pharmacokinetics of etretinate, acitretin and 13-cis-acitretin: new results and advantages of blood level oriented clinical use]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139274/),[ng] / [ml],161,92657,DB00755,Tretinoin
,2139274,Cmax-levels,The plasma concentration profile of 13-cis A. was plateau-like with Cmax-levels of 138 ng/ml after 4 to 10 hours.,"[Pharmacokinetics of etretinate, acitretin and 13-cis-acitretin: new results and advantages of blood level oriented clinical use]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139274/),[ng] / [ml],138,92658,DB00755,Tretinoin
,2139274,Cmax,"In group B treated with 0.3 to 0.4 mg/kg etretinate a trend to increased Cmax-values with 123 ng/ml for E., 44 ng/ml for A. and, more pronounced, 210 ng/ml for 13-cis A. occurred (steady state).","[Pharmacokinetics of etretinate, acitretin and 13-cis-acitretin: new results and advantages of blood level oriented clinical use]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139274/),[ng] / [ml],123,92659,DB00755,Tretinoin
,2139274,Cmax,"In group B treated with 0.3 to 0.4 mg/kg etretinate a trend to increased Cmax-values with 123 ng/ml for E., 44 ng/ml for A. and, more pronounced, 210 ng/ml for 13-cis A. occurred (steady state).","[Pharmacokinetics of etretinate, acitretin and 13-cis-acitretin: new results and advantages of blood level oriented clinical use]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139274/),[ng] / [ml],44,92660,DB00755,Tretinoin
,2139274,Cmax,"In group B treated with 0.3 to 0.4 mg/kg etretinate a trend to increased Cmax-values with 123 ng/ml for E., 44 ng/ml for A. and, more pronounced, 210 ng/ml for 13-cis A. occurred (steady state).","[Pharmacokinetics of etretinate, acitretin and 13-cis-acitretin: new results and advantages of blood level oriented clinical use]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139274/),[ng] / [ml],210,92661,DB00755,Tretinoin
,10423603,area under the curve (AUC),Median area under the curve (AUC) decreased from a baseline level of 1.2 to 0.69 microg/ml/h (p = 0.03).,Restoration of oral all-trans retinoic acid bioavailability after a brief drug holiday. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423603/),[μg] / [h·ml],1.2,93037,DB00755,Tretinoin
,10423603,area under the curve (AUC),Median area under the curve (AUC) decreased from a baseline level of 1.2 to 0.69 microg/ml/h (p = 0.03).,Restoration of oral all-trans retinoic acid bioavailability after a brief drug holiday. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423603/),[μg] / [h·ml],0.69,93038,DB00755,Tretinoin
,10423603,AUC,After a 7-day drug holiday the median AUC significantly increased from the day 7 value to 1.8 microg/ml/h p = 0.01).,Restoration of oral all-trans retinoic acid bioavailability after a brief drug holiday. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423603/),[μg] / [h·ml],1.8,93039,DB00755,Tretinoin
,9035347,0-24-h,"All-trans-RA reached much lower plasma concentrations after the last two treatments on GD 31 than after the first one on GD 16 and the eleventh one on GD 26 (0-24-h area-under-the-concentration-time-curve (AUC) values: 104 +/- 59 ng x h/ml (after the last treatment on GD 31), 189 +/- 110 (GD 16) and 393 +/- 305 ng x h/ml (GD 26).",Retinoid metabolism and transplacental pharmacokinetics in the cynomolgus monkey following a nonteratogenic dosing regimen with all-trans-retinoic acid. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9035347/),[h·ng] / [ml],104,97836,DB00755,Tretinoin
,9035347,area-under-the-concentration-time-curve (AUC),"All-trans-RA reached much lower plasma concentrations after the last two treatments on GD 31 than after the first one on GD 16 and the eleventh one on GD 26 (0-24-h area-under-the-concentration-time-curve (AUC) values: 104 +/- 59 ng x h/ml (after the last treatment on GD 31), 189 +/- 110 (GD 16) and 393 +/- 305 ng x h/ml (GD 26).",Retinoid metabolism and transplacental pharmacokinetics in the cynomolgus monkey following a nonteratogenic dosing regimen with all-trans-retinoic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9035347/),[h·ng] / [ml],104,97837,DB00755,Tretinoin
,9035347,area-under-the-concentration-time-curve (AUC),"All-trans-RA reached much lower plasma concentrations after the last two treatments on GD 31 than after the first one on GD 16 and the eleventh one on GD 26 (0-24-h area-under-the-concentration-time-curve (AUC) values: 104 +/- 59 ng x h/ml (after the last treatment on GD 31), 189 +/- 110 (GD 16) and 393 +/- 305 ng x h/ml (GD 26).",Retinoid metabolism and transplacental pharmacokinetics in the cynomolgus monkey following a nonteratogenic dosing regimen with all-trans-retinoic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9035347/),[h·ng] / [ml],189,97838,DB00755,Tretinoin
,9035347,area-under-the-concentration-time-curve (AUC),"All-trans-RA reached much lower plasma concentrations after the last two treatments on GD 31 than after the first one on GD 16 and the eleventh one on GD 26 (0-24-h area-under-the-concentration-time-curve (AUC) values: 104 +/- 59 ng x h/ml (after the last treatment on GD 31), 189 +/- 110 (GD 16) and 393 +/- 305 ng x h/ml (GD 26).",Retinoid metabolism and transplacental pharmacokinetics in the cynomolgus monkey following a nonteratogenic dosing regimen with all-trans-retinoic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9035347/),[h·ng] / [ml],393,97839,DB00755,Tretinoin
,1535045,area under the insulin-time curve,"The area under the insulin-time curve (baseline corrected) was significantly decreased from 1.20 mU.min.l-1 on Day 1 to 0.89 mU.min.l-1 on Day 10, and was 0.91 mU.min.l-1 on Day 24.",Effect of acitretin on the response to an intravenous glucose tolerance test in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535045/),[min·mu] / [l],1.20,100352,DB00755,Tretinoin
,1535045,area under the insulin-time curve,"The area under the insulin-time curve (baseline corrected) was significantly decreased from 1.20 mU.min.l-1 on Day 1 to 0.89 mU.min.l-1 on Day 10, and was 0.91 mU.min.l-1 on Day 24.",Effect of acitretin on the response to an intravenous glucose tolerance test in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535045/),[min·mu] / [l],0.89,100353,DB00755,Tretinoin
,1535045,area under the insulin-time curve,"The area under the insulin-time curve (baseline corrected) was significantly decreased from 1.20 mU.min.l-1 on Day 1 to 0.89 mU.min.l-1 on Day 10, and was 0.91 mU.min.l-1 on Day 24.",Effect of acitretin on the response to an intravenous glucose tolerance test in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535045/),[min·mu] / [l],0.91,100354,DB00755,Tretinoin
,1535045,insulin sensitivity',The model-derived 'insulin sensitivity' increased from 13.10(-4) l.mU-1.min-1 on Day 1 to 20.10(-4) l.mU-1.min-1 on Day 10 and was 18.10(-4) l.mU-1.min-1 on Day 24.,Effect of acitretin on the response to an intravenous glucose tolerance test in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535045/),[l] / [min·mu],13.10(-4),100355,DB00755,Tretinoin
,1535045,insulin sensitivity',The model-derived 'insulin sensitivity' increased from 13.10(-4) l.mU-1.min-1 on Day 1 to 20.10(-4) l.mU-1.min-1 on Day 10 and was 18.10(-4) l.mU-1.min-1 on Day 24.,Effect of acitretin on the response to an intravenous glucose tolerance test in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535045/),[l] / [min·mu],20.10(-4),100356,DB00755,Tretinoin
,1535045,insulin sensitivity',The model-derived 'insulin sensitivity' increased from 13.10(-4) l.mU-1.min-1 on Day 1 to 20.10(-4) l.mU-1.min-1 on Day 10 and was 18.10(-4) l.mU-1.min-1 on Day 24.,Effect of acitretin on the response to an intravenous glucose tolerance test in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535045/),[l] / [min·mu],18.10(-4),100357,DB00755,Tretinoin
,8806847,Km,"For mice dosed i.v. (10 mg/kg), there was a saturated phase of elimination of RA from plasma (Km = 0.61 microgram/ml and Vmax = 2572 micrograms/hr); no such phase was noted when UAB-8 was administered.","Murine toxicology and pharmacology of UAB-8, a conformationally constrained analog of retinoic acid. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8806847/),[μg] / [ml],0.61,101965,DB00755,Tretinoin
,8806847,Vmax,"For mice dosed i.v. (10 mg/kg), there was a saturated phase of elimination of RA from plasma (Km = 0.61 microgram/ml and Vmax = 2572 micrograms/hr); no such phase was noted when UAB-8 was administered.","Murine toxicology and pharmacology of UAB-8, a conformationally constrained analog of retinoic acid. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8806847/),[μg] / [h],2572,101966,DB00755,Tretinoin
,8806847,t1/2 alpha,"UAB-8 had values for t1/2 alpha and t1/2 beta of 0.47 and 17.1 hr, respectively.","Murine toxicology and pharmacology of UAB-8, a conformationally constrained analog of retinoic acid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8806847/),h,0.47,101967,DB00755,Tretinoin
,8806847,t1/2 beta,"UAB-8 had values for t1/2 alpha and t1/2 beta of 0.47 and 17.1 hr, respectively.","Murine toxicology and pharmacology of UAB-8, a conformationally constrained analog of retinoic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8806847/),h,17.1,101968,DB00755,Tretinoin
,2141075,systemic clearance (CLs),"The systemic clearance (CLs) of etretinate and the formation clearance (CLf) of the metabolite (acitretin) were lower in the obese rats (132 and 62.4 mL/min, respectively) compared with their lean littermates (197 and 126 mL/min, respectively).",Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),[ml] / [min],132,102769,DB00755,Tretinoin
,2141075,systemic clearance (CLs),"The systemic clearance (CLs) of etretinate and the formation clearance (CLf) of the metabolite (acitretin) were lower in the obese rats (132 and 62.4 mL/min, respectively) compared with their lean littermates (197 and 126 mL/min, respectively).",Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),[ml] / [min],62.4,102770,DB00755,Tretinoin
,2141075,systemic clearance (CLs),"The systemic clearance (CLs) of etretinate and the formation clearance (CLf) of the metabolite (acitretin) were lower in the obese rats (132 and 62.4 mL/min, respectively) compared with their lean littermates (197 and 126 mL/min, respectively).",Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),[ml] / [min],197,102771,DB00755,Tretinoin
,2141075,formation clearance (CLf),"The systemic clearance (CLs) of etretinate and the formation clearance (CLf) of the metabolite (acitretin) were lower in the obese rats (132 and 62.4 mL/min, respectively) compared with their lean littermates (197 and 126 mL/min, respectively).",Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),[ml] / [min],62.4,102772,DB00755,Tretinoin
,2141075,formation clearance (CLf),"The systemic clearance (CLs) of etretinate and the formation clearance (CLf) of the metabolite (acitretin) were lower in the obese rats (132 and 62.4 mL/min, respectively) compared with their lean littermates (197 and 126 mL/min, respectively).",Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),[ml] / [min],197,102773,DB00755,Tretinoin
,2141075,formation clearance (CLf),"The systemic clearance (CLs) of etretinate and the formation clearance (CLf) of the metabolite (acitretin) were lower in the obese rats (132 and 62.4 mL/min, respectively) compared with their lean littermates (197 and 126 mL/min, respectively).",Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),[ml] / [min],126,102774,DB00755,Tretinoin
,2141075,metabolic clearance (CLd),"The remaining metabolic clearance (CLd) was identical for the lean and obese animals (70.9 and 69.9 mL/min, respectively).",Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),[ml] / [min],70.9,102775,DB00755,Tretinoin
,2141075,metabolic clearance (CLd),"The remaining metabolic clearance (CLd) was identical for the lean and obese animals (70.9 and 69.9 mL/min, respectively).",Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),[ml] / [min],69.9,102776,DB00755,Tretinoin
,2141075,terminal phase half-life (t1/2),The terminal phase half-life (t1/2) was significantly longer in the obese rats (3.52 versus 1.25 h).,Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),h,3.52,102777,DB00755,Tretinoin
,2141075,terminal phase half-life (t1/2),The terminal phase half-life (t1/2) was significantly longer in the obese rats (3.52 versus 1.25 h).,Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),h,1.25,102778,DB00755,Tretinoin
,7738627,area under the plasma concentration-time curve (AUC),"Plasma exposure to ATRA as measured by the area under the plasma concentration-time curve (AUC) decreased significantly during the first week of drug administration, from a mean of 145 +/- 26 mumol/L.min on day 1 to 18 +/- 4 mumol/L.min by day 7.",Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738627/),[μM] / [l·min],145,106033,DB00755,Tretinoin
,7738627,area under the plasma concentration-time curve (AUC),"Plasma exposure to ATRA as measured by the area under the plasma concentration-time curve (AUC) decreased significantly during the first week of drug administration, from a mean of 145 +/- 26 mumol/L.min on day 1 to 18 +/- 4 mumol/L.min by day 7.",Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738627/),[μM] / [l·min],18,106034,DB00755,Tretinoin
,7738627,AUCs,"Plasma ATRA concentrations at the start of weeks 3 and 11 of this every-other-week schedule were equivalent to those achieved on day 1 of treatment, with mean AUCs of 177 +/- 39 and 128 +/- 30 mumol/L.min, respectively.",Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738627/),[μM] / [l·min],177,106035,DB00755,Tretinoin
,7738627,AUCs,"Plasma ATRA concentrations at the start of weeks 3 and 11 of this every-other-week schedule were equivalent to those achieved on day 1 of treatment, with mean AUCs of 177 +/- 39 and 128 +/- 30 mumol/L.min, respectively.",Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738627/),[μM] / [l·min],128,106036,DB00755,Tretinoin
,6126340,t1/2,"Serum levels of the drugs reached their maxima within 15-30 min and then declined in an exponential fashion with t1/2 values of 19 min and 2.9 hr, respectively.",Disposition of 13-cis-retinoic acid and N-(2-hydroxyethyl)retinamide in mice after oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126340/),min,19,106582,DB00755,Tretinoin
,6126340,t1/2,"Serum levels of the drugs reached their maxima within 15-30 min and then declined in an exponential fashion with t1/2 values of 19 min and 2.9 hr, respectively.",Disposition of 13-cis-retinoic acid and N-(2-hydroxyethyl)retinamide in mice after oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126340/),h,2.9,106583,DB00755,Tretinoin
,6126340,t1/2,"Tissue levels of 13-cis-retinoic acid reached their maxima within 15-30 min, then declined exponentially with t1/2 values of 11-19 min.",Disposition of 13-cis-retinoic acid and N-(2-hydroxyethyl)retinamide in mice after oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126340/),min,11-19,106584,DB00755,Tretinoin
,6126340,t1/2,"Tissue levels of N-(2-hydroxyethyl)retinamide reached their maxima within 30 min to 2 hr, then declined exponentially with t1/2 values of 2.1-4.7 hr.",Disposition of 13-cis-retinoic acid and N-(2-hydroxyethyl)retinamide in mice after oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126340/),h,2.1-4.7,106585,DB00755,Tretinoin
,6126340,t1/2,"Longer t1/2 values were observed for both 13-cis-retinoic acid and N-(2-hydroxyethyl)retinamide in the bladder (51 min and 7.3 hr, respectively).",Disposition of 13-cis-retinoic acid and N-(2-hydroxyethyl)retinamide in mice after oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126340/),min,51,106586,DB00755,Tretinoin
,6126340,t1/2,"Longer t1/2 values were observed for both 13-cis-retinoic acid and N-(2-hydroxyethyl)retinamide in the bladder (51 min and 7.3 hr, respectively).",Disposition of 13-cis-retinoic acid and N-(2-hydroxyethyl)retinamide in mice after oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126340/),h,7.3,106587,DB00755,Tretinoin
,6138231,elimination half-life (t 1/2 beta),The harmonic mean elimination half-life (t 1/2 beta) for the simultaneous iv and oral administration was approximately 5.5 hr.,"Role of gut contents, intestinal wall, and liver on the first pass metabolism and absolute bioavailability of isotretinoin in the dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138231/),h,5.5,109163,DB00755,Tretinoin
,6138231,blood clearance (ClB),"The mean +/- SD blood clearance (ClB) following iv administration and the intrinsic clearance following oral administration were 5.19 +/- 2.40 and 6.63 +/- 3.72 ml/min/kg, respectively.","Role of gut contents, intestinal wall, and liver on the first pass metabolism and absolute bioavailability of isotretinoin in the dog. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138231/),[ml] / [kg·min],5.19,109164,DB00755,Tretinoin
,6138231,intrinsic clearance,"The mean +/- SD blood clearance (ClB) following iv administration and the intrinsic clearance following oral administration were 5.19 +/- 2.40 and 6.63 +/- 3.72 ml/min/kg, respectively.","Role of gut contents, intestinal wall, and liver on the first pass metabolism and absolute bioavailability of isotretinoin in the dog. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138231/),[ml] / [kg·min],6.63,109165,DB00755,Tretinoin
,6138231,absolute bioavailability,"The average absolute bioavailability was 21%, indicating an overall first pass effect of approximately 80%.","Role of gut contents, intestinal wall, and liver on the first pass metabolism and absolute bioavailability of isotretinoin in the dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138231/),%,21,109166,DB00755,Tretinoin
,2882980,terminal half-life,"With this procedure, we have determined the terminal half-life for RA (0.5 hr) and have confirmed the half-life for NHERA (3.6 hr) in the plasma of mice dosed orally.",The pharmacokinetics of all-trans-retinoic acid and N-(2-hydroxyethyl)retinamide in mice as determined with a sensitive and convenient procedure. Solid-phase extraction and reverse-phase high performance liquid chromatography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882980/),h,0.5,109321,DB00755,Tretinoin
,2882980,half-life,"With this procedure, we have determined the terminal half-life for RA (0.5 hr) and have confirmed the half-life for NHERA (3.6 hr) in the plasma of mice dosed orally.",The pharmacokinetics of all-trans-retinoic acid and N-(2-hydroxyethyl)retinamide in mice as determined with a sensitive and convenient procedure. Solid-phase extraction and reverse-phase high performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882980/),h,3.6,109322,DB00755,Tretinoin
,2977392,AUC0-15,The AUC0-15 for acitretin was increased when administered with food for all subjects (except one) with a mean increase of 90% (from 1175 to 2249 ng/ml.hr).,Food increases the bioavailability of acitretin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2977392/),,224,111565,DB00755,Tretinoin
,2977392,maximum plasma concentration of acitretin (Cmax),"The maximum plasma concentration of acitretin (Cmax) was increased by 70% when administered with food (from 245 to 416 ng/ml), while the time to reach Cmax was unaffected.",Food increases the bioavailability of acitretin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2977392/),[ng] / [ml],245,111566,DB00755,Tretinoin
,2977392,maximum plasma concentration of acitretin (Cmax),"The maximum plasma concentration of acitretin (Cmax) was increased by 70% when administered with food (from 245 to 416 ng/ml), while the time to reach Cmax was unaffected.",Food increases the bioavailability of acitretin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2977392/),[ng] / [ml],416,111567,DB00755,Tretinoin
,7967727,maximum tolerated dose (MTD),"We previously performed a standard pediatric phase I trial of ATRA and defined the maximum tolerated dose (MTD) in children to be 60 mg/m2/day, significantly lower than the MTD in adult patients.",Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7967727/),[mg] / [d·m2],60,113029,DB00755,Tretinoin
,7967727,plasma half-life,"Pharmacokinetic results revealed that the plasma half-life of ATRA was short (45 min) relative to 13-cis-RA (12-24 h), and that plasma drug exposure decreased significantly by day 28 of daily drug administration.",Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7967727/),min,45,113030,DB00755,Tretinoin
,7967727,plasma half-life,"Pharmacokinetic results revealed that the plasma half-life of ATRA was short (45 min) relative to 13-cis-RA (12-24 h), and that plasma drug exposure decreased significantly by day 28 of daily drug administration.",Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7967727/),h,12-24,113031,DB00755,Tretinoin
,9025776,Apparent clearance,"Apparent clearance of ATRA changed substantially during therapy: day 1 3779 +/- 4215 ml/min, day 14 7179 +/- 3197 ml/min, day 22 3213 +/- 2357 ml/min.",A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9025776/),[ml] / [min],3779,115397,DB00755,Tretinoin
,9025776,Apparent clearance,"Apparent clearance of ATRA changed substantially during therapy: day 1 3779 +/- 4215 ml/min, day 14 7179 +/- 3197 ml/min, day 22 3213 +/- 2357 ml/min.",A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9025776/),[ml] / [min],7179,115398,DB00755,Tretinoin
,9025776,Apparent clearance,"Apparent clearance of ATRA changed substantially during therapy: day 1 3779 +/- 4215 ml/min, day 14 7179 +/- 3197 ml/min, day 22 3213 +/- 2357 ml/min.",A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9025776/),[ml] / [min],3213,115399,DB00755,Tretinoin
,2573489,Vdss,The large Vdss (214 +/- 228 liters/kg) of ET and terminal half-life of greater than 300 hr indicated the wide distribution and prolonged storage of ET in the tissues.,The pharmacokinetics of etretinate and its metabolites in the dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573489/),[l] / [kg],214,116235,DB00755,Tretinoin
greater,2573489,terminal half-life,The large Vdss (214 +/- 228 liters/kg) of ET and terminal half-life of greater than 300 hr indicated the wide distribution and prolonged storage of ET in the tissues.,The pharmacokinetics of etretinate and its metabolites in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573489/),h,300,116236,DB00755,Tretinoin
,2573489,oral bioavailability,The oral bioavailability of ET in the dog was 52.5% with 95.4% of the dose available for absorption from the gut lumen.,The pharmacokinetics of etretinate and its metabolites in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573489/),%,52.5,116237,DB00755,Tretinoin
,2573489,oral bioavailability,The oral bioavailability of ET in the dog was 52.5% with 95.4% of the dose available for absorption from the gut lumen.,The pharmacokinetics of etretinate and its metabolites in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573489/),%,95,116238,DB00755,Tretinoin
,2573489,oral bioavailability,"Although the oral bioavailability of ETA could not be determined because its administration was not possible by the iv route, it appeared that only 16% of an orally administered dose entered the portal circulation from the gut.",The pharmacokinetics of etretinate and its metabolites in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573489/),,16,116239,DB00755,Tretinoin
,2573489,oral bioavailability,"The oral bioavailability of c-ETA was 42.4%, but the liver showed little metabolic activity toward c-ETA.(ABSTRACT TRUNCATED AT 250 WORDS)",The pharmacokinetics of etretinate and its metabolites in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573489/),%,42.4,116240,DB00755,Tretinoin
,2141193,concentration quotient,"The concentration quotient between embryo and the maternal plasma was between 0.43 and 1.10 for all-trans-etretin, and only 0.16-0.31 for 13-cis-etretin over the time period studied.",Teratogenicity of the 13-cis and all-trans-isomers of the aromatic retinoid etretin: correlation to transplacental pharmacokinetics in mice during organogenesis after a single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141193/),,0.43 and 1.10,116707,DB00755,Tretinoin
,2141193,concentration quotient,"The concentration quotient between embryo and the maternal plasma was between 0.43 and 1.10 for all-trans-etretin, and only 0.16-0.31 for 13-cis-etretin over the time period studied.",Teratogenicity of the 13-cis and all-trans-isomers of the aromatic retinoid etretin: correlation to transplacental pharmacokinetics in mice during organogenesis after a single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141193/),,0.16-0.31,116708,DB00755,Tretinoin
,19127869,T(1/2),"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),h,11.28,120465,DB00755,Tretinoin
,19127869,T(1/2),"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),h,8.90,120466,DB00755,Tretinoin
,19127869,T(1/2),"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),h,8.01,120467,DB00755,Tretinoin
,19127869,AUC(0-infinity),"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),[h·ng] / [ml],103.41,120468,DB00755,Tretinoin
,19127869,AUC(0-infinity),"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),[h·ng] / [ml],190.23,120469,DB00755,Tretinoin
,19127869,AUC(0-infinity),"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),[h·ng] / [ml],421.66,120470,DB00755,Tretinoin
,19127869,MRT,"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),h,6.31,120471,DB00755,Tretinoin
,19127869,MRT,"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),h,5.98,120472,DB00755,Tretinoin
,19127869,MRT,"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),h,6.18,120473,DB00755,Tretinoin
,19127869,CL/F,"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),[l] / [h·kg],30.10,120474,DB00755,Tretinoin
,19127869,CL/F,"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),[l] / [h·kg],29.58,120475,DB00755,Tretinoin
,19127869,CL/F,"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),[l] / [h·kg],31.18,120476,DB00755,Tretinoin
,19127869,Vd/F,"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),,414.94,120477,DB00755,Tretinoin
greater,6960001,recoveries,Precisions are all less than 8% with recoveries greater than 80%.,"HPLC, MS, and pharmacokinetics of melphalan, bisantrene and 13-cis retinoic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6960001/),%,80,125701,DB00755,Tretinoin
<,10657762,T(max),The distribution of 9-cis-retinoic acid was rapid in all of the organs studied (T(max) </=2 h).,Kinetics of plasma and tissue distribution of 9-cis-retinoic acid in rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657762/),h,2,127210,DB00755,Tretinoin
,6113925,t 1/2,"Tissue levels reached a maximum within 30 to 120 min, then declined after 3 hr in an exponential fashion with t 1/2 values of 25 to 68 min.",Disposition of all-trans-retinoic acid in mice following oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6113925/),min,25 to 68,133119,DB00755,Tretinoin
,1774953,time to peak concentration,"In the other patients, the time to peak concentration of all-trans RA was between 60 and 210 min (median 90 min) after ingestion, with maximum concentrations between 0.03 and 2.5 micrograms/ml (median 0.4 micrograms/ml).",Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774953/),min,60 and 210,133923,DB00755,Tretinoin
,1774953,time to peak concentration,"In the other patients, the time to peak concentration of all-trans RA was between 60 and 210 min (median 90 min) after ingestion, with maximum concentrations between 0.03 and 2.5 micrograms/ml (median 0.4 micrograms/ml).",Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774953/),min,90,133924,DB00755,Tretinoin
,1774953,maximum concentrations,"In the other patients, the time to peak concentration of all-trans RA was between 60 and 210 min (median 90 min) after ingestion, with maximum concentrations between 0.03 and 2.5 micrograms/ml (median 0.4 micrograms/ml).",Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774953/),[μg] / [ml],0.03 and 2.5,133925,DB00755,Tretinoin
,1774953,maximum concentrations,"In the other patients, the time to peak concentration of all-trans RA was between 60 and 210 min (median 90 min) after ingestion, with maximum concentrations between 0.03 and 2.5 micrograms/ml (median 0.4 micrograms/ml).",Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774953/),[μg] / [ml],0.4,133926,DB00755,Tretinoin
,1774953,apparent plasma elimination half-life,The apparent plasma elimination half-life was between 16.8 and 77.4 min (median 30 min).,Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774953/),min,30,133927,DB00755,Tretinoin
,8230282,AUC,"Following continuous oral treatment, the mean day 28 AUC for all-trans RA was significantly lower than that on day 1 (213 ng/mL per hour versus 467 ng/mL per hour; P < .01), a decline significantly attenuated by ketoconazole, which increased the mean plasma all-trans RA AUC on day 29 to 375 ng/mL per hour (P < .01).","Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230282/),[ng] / [h·ml],213,134769,DB00755,Tretinoin
,8230282,AUC,"Following continuous oral treatment, the mean day 28 AUC for all-trans RA was significantly lower than that on day 1 (213 ng/mL per hour versus 467 ng/mL per hour; P < .01), a decline significantly attenuated by ketoconazole, which increased the mean plasma all-trans RA AUC on day 29 to 375 ng/mL per hour (P < .01).","Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230282/),[ng] / [h·ml],467,134770,DB00755,Tretinoin
,8230282,AUC,"Following continuous oral treatment, the mean day 28 AUC for all-trans RA was significantly lower than that on day 1 (213 ng/mL per hour versus 467 ng/mL per hour; P < .01), a decline significantly attenuated by ketoconazole, which increased the mean plasma all-trans RA AUC on day 29 to 375 ng/mL per hour (P < .01).","Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230282/),[ng] / [h·ml],375,134771,DB00755,Tretinoin
,14581068,flow rate,"All-trans RA, 9-cRA, and 13-cRA were well separated from each other in plasma by using a C18 precolumn and a column with a gradient solvent system of mobile phases A and B at a flow rate of 1.0 ml/min.",Novel inhibition of cis/trans retinoic acid interconversion in biological fluids--an accurate method for determination of trans and 13-cis retinoic acid in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581068/),[ml] / [min],1.0,138219,DB00755,Tretinoin
,14581068,C,"C to inhibit the interconversion were 50 and 150 microM, respectively, (2) higher concentrations of NEM and Vit.",Novel inhibition of cis/trans retinoic acid interconversion in biological fluids--an accurate method for determination of trans and 13-cis retinoic acid in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581068/),μM,50,138220,DB00755,Tretinoin
,14581068,C,"C to inhibit the interconversion were 50 and 150 microM, respectively, (2) higher concentrations of NEM and Vit.",Novel inhibition of cis/trans retinoic acid interconversion in biological fluids--an accurate method for determination of trans and 13-cis retinoic acid in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581068/),μM,150,138221,DB00755,Tretinoin
,14581068,recovery,"C were required to prevent the interconversion at higher temperature, (3) the precision and accuracy of calibration curve with various concentration of tRA (1-1000 ng/ml) and 13-cRA (5-800 ng/ml) in plasma showed good linearity (r(2)=0.9992 and 0.9994), and between-day errors expressed by coefficient of variation (CV, %) for tRA and 13-cRA which were both less than 5.6%, (4) the mean recovery of the analytes were 78-94% for tRA and 80-92% for 13-cRA at concentration range from 1 to 1000 ng/ml and 5 to 800 ng/ml, respectively, and (5) the limit of quantitation of tRA and 13-cRA were 1 and 5 ng/ml, respectively.",Novel inhibition of cis/trans retinoic acid interconversion in biological fluids--an accurate method for determination of trans and 13-cis retinoic acid in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581068/),%,78-94,138222,DB00755,Tretinoin
,14581068,recovery,"C were required to prevent the interconversion at higher temperature, (3) the precision and accuracy of calibration curve with various concentration of tRA (1-1000 ng/ml) and 13-cRA (5-800 ng/ml) in plasma showed good linearity (r(2)=0.9992 and 0.9994), and between-day errors expressed by coefficient of variation (CV, %) for tRA and 13-cRA which were both less than 5.6%, (4) the mean recovery of the analytes were 78-94% for tRA and 80-92% for 13-cRA at concentration range from 1 to 1000 ng/ml and 5 to 800 ng/ml, respectively, and (5) the limit of quantitation of tRA and 13-cRA were 1 and 5 ng/ml, respectively.",Novel inhibition of cis/trans retinoic acid interconversion in biological fluids--an accurate method for determination of trans and 13-cis retinoic acid in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581068/),%,80-92,138223,DB00755,Tretinoin
,2575502,steady state trough plasma concentrations,"During a multiple dose regimen of etretinate, steady state trough plasma concentrations of etretinate in nonpregnant female rats reached their peak levels (15 ng/ml) by day 10 and remained between 10 and 15 ng/ml through day 19.",Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. Single and multiple oral dosing studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575502/),[ng] / [ml],15,139926,DB00755,Tretinoin
,2575502,steady state trough plasma concentrations,"During a multiple dose regimen of etretinate, steady state trough plasma concentrations of etretinate in nonpregnant female rats reached their peak levels (15 ng/ml) by day 10 and remained between 10 and 15 ng/ml through day 19.",Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. Single and multiple oral dosing studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575502/),[ng] / [ml],10 and 15,139927,DB00755,Tretinoin
,2575502,Steady state trough concentrations,Steady state trough concentrations of acitretin in nonpregnant animals following etretinate multiple dosing reached their peak levels (53 ng/ml) at day 7 and declined to 16 ng/ml at day 19.,Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. Single and multiple oral dosing studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575502/),[ng] / [ml],53,139928,DB00755,Tretinoin
,2575502,Steady state trough concentrations,Steady state trough concentrations of acitretin in nonpregnant animals following etretinate multiple dosing reached their peak levels (53 ng/ml) at day 7 and declined to 16 ng/ml at day 19.,Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. Single and multiple oral dosing studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575502/),[ng] / [ml],16,139929,DB00755,Tretinoin
,2575502,apparent oral bioavailability,"In single dose studies, the apparent oral bioavailability of etretinate was similar (4-5%) for both pregnant and nonpregnant rats (p greater than 0.05).",Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. Single and multiple oral dosing studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575502/),%,4-5,139930,DB00755,Tretinoin
,2575502,bioavailability,"Acitretin bioavailability was 10-fold greater than that for etretinate (57%); again, there was no difference between the pregnant and nonpregnant groups (p greater than 0.05).",Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. Single and multiple oral dosing studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575502/),%,57,139931,DB00755,Tretinoin
,8388479,peak concentrations,"Plasma concentrations following an oral dose of all-trans-RA were highly variable, with peak concentrations ranging from 0.07 to 1.2 microM for the 78-mg/m2 dose level.",Variability in the oral bioavailability of all-trans-retinoic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388479/),μM,0.07 to 1.2,140397,DB00755,Tretinoin
,15881331,area under the curve (AUC),The area under the curve (AUC) was significantly higher in the tretinoin self-emulsifying formulation group (3048.0 mg x h x L(-1)) than that in the commercial capsule group (1826.0 mg x h x L(-1)).,[Assesement of tretinoin with a self-emulsifying formulation in vitro and in vivo]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881331/),[h·mg] / [l],3048.0,141808,DB00755,Tretinoin
,15881331,area under the curve (AUC),The area under the curve (AUC) was significantly higher in the tretinoin self-emulsifying formulation group (3048.0 mg x h x L(-1)) than that in the commercial capsule group (1826.0 mg x h x L(-1)).,[Assesement of tretinoin with a self-emulsifying formulation in vitro and in vivo]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881331/),[h·mg] / [l],1826.0,141809,DB00755,Tretinoin
,15881331,Tmax,"Also, Tmax was smaller in the self-emulsifying formulation group (1.25 h) compared with market products (2 h) and the dissolved amount from self-emulsifying formulations in water at 15 min was much higher (more than 80%) than that of the market products (less than 5%).",[Assesement of tretinoin with a self-emulsifying formulation in vitro and in vivo]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881331/),h,1.25,141810,DB00755,Tretinoin
,15881331,Tmax,"Also, Tmax was smaller in the self-emulsifying formulation group (1.25 h) compared with market products (2 h) and the dissolved amount from self-emulsifying formulations in water at 15 min was much higher (more than 80%) than that of the market products (less than 5%).",[Assesement of tretinoin with a self-emulsifying formulation in vitro and in vivo]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881331/),h,2,141811,DB00755,Tretinoin
,1971569,t1/2,"The t1/2 for MPR was 5.1 hr in liver, 5.6 hr in serum, 18.7 hr in urinary bladder, 23.1 hr in skin, and 26.6 hr in mammary gland.","Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971569/),h,5.1,144508,DB00755,Tretinoin
,1971569,t1/2,"The t1/2 for MPR was 5.1 hr in liver, 5.6 hr in serum, 18.7 hr in urinary bladder, 23.1 hr in skin, and 26.6 hr in mammary gland.","Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971569/),h,5.6,144509,DB00755,Tretinoin
,1971569,t1/2,"The t1/2 for MPR was 5.1 hr in liver, 5.6 hr in serum, 18.7 hr in urinary bladder, 23.1 hr in skin, and 26.6 hr in mammary gland.","Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971569/),h,18.7,144510,DB00755,Tretinoin
,1971569,t1/2,"The t1/2 for MPR was 5.1 hr in liver, 5.6 hr in serum, 18.7 hr in urinary bladder, 23.1 hr in skin, and 26.6 hr in mammary gland.","Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971569/),h,23.1,144511,DB00755,Tretinoin
,1971569,t1/2,"The t1/2 for MPR was 5.1 hr in liver, 5.6 hr in serum, 18.7 hr in urinary bladder, 23.1 hr in skin, and 26.6 hr in mammary gland.","Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971569/),h,26.6,144512,DB00755,Tretinoin
,2147001,terminal half-life,"Because of the long terminal half-life of this drug (100 days), considerable plasma levels of etretinate and its main metabolite, etretin (acitretin), were observed for up to 2 years following discontinuation of therapy.",Teratogenicity of steady-state concentrations of etretinate and metabolite acitretin maintained in maternal plasma and embryo by intragastric infusion during organogenesis in the mouse: a possible model for the extended elimination phase in human therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2147001/),d,100,147806,DB00755,Tretinoin
,24445345,flow rate,"The mobile phase was consisted of 40% phase A (MTBE-methanol-acetic acid, 50:50:0.5, v/v) and 60% phase B (water-methanol-acetic acid, 50:50:0.5, v/v) with a flow rate of 0.3 mL/min.",Validation of a liquid chromatography-electrospray ionization-tandem mass spectrometry method for determination of all-trans retinoic acid in human plasma and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24445345/),[ml] / [min],0.3,152682,DB00755,Tretinoin
,24445345,m/,"The API 4000 triple quadrupole mass spectrometer was operated in multiple reaction monitoring (MRM) mode via the positive electrospray ionization interface using the transition m/z 301.4→123.1 for ATRA and m/z 326.9→177.1 for IS, respectively.",Validation of a liquid chromatography-electrospray ionization-tandem mass spectrometry method for determination of all-trans retinoic acid in human plasma and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24445345/),,326.9,152683,DB00755,Tretinoin
,29235901,CMC,The 7:3 and 5:5 micellar combinations had lower CMC values (0.034-0.042 mg/mL) than 0:10 (0.124 mg/mL).,"A novel mixed polymeric micelle for co-delivery of paclitaxel and retinoic acid and overcoming multidrug resistance: synthesis, characterization, cytotoxicity, and pharmacokinetic evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29235901/),[mg] / [ml],0.034-0.042,154921,DB00755,Tretinoin
,29235901,CMC,The 7:3 and 5:5 micellar combinations had lower CMC values (0.034-0.042 mg/mL) than 0:10 (0.124 mg/mL).,"A novel mixed polymeric micelle for co-delivery of paclitaxel and retinoic acid and overcoming multidrug resistance: synthesis, characterization, cytotoxicity, and pharmacokinetic evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29235901/),[mg] / [ml],0.124,154922,DB00755,Tretinoin
,29235901,entrapment efficiencies,"The entrapment efficiencies of 10:0, 7:3, and 5:5 were 53.4 ± 9.3%, 61.3 ± 0.5%, and 78.7 ± 1.66%, respectively.","A novel mixed polymeric micelle for co-delivery of paclitaxel and retinoic acid and overcoming multidrug resistance: synthesis, characterization, cytotoxicity, and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29235901/),%,53.4,154923,DB00755,Tretinoin
,29235901,entrapment efficiencies,"The entrapment efficiencies of 10:0, 7:3, and 5:5 were 53.4 ± 9.3%, 61.3 ± 0.5%, and 78.7 ± 1.66%, respectively.","A novel mixed polymeric micelle for co-delivery of paclitaxel and retinoic acid and overcoming multidrug resistance: synthesis, characterization, cytotoxicity, and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29235901/),%,61.3,154924,DB00755,Tretinoin
,29235901,entrapment efficiencies,"The entrapment efficiencies of 10:0, 7:3, and 5:5 were 53.4 ± 9.3%, 61.3 ± 0.5%, and 78.7 ± 1.66%, respectively.","A novel mixed polymeric micelle for co-delivery of paclitaxel and retinoic acid and overcoming multidrug resistance: synthesis, characterization, cytotoxicity, and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29235901/),%,78.7,154925,DB00755,Tretinoin
,2959917,lag-time,"In patients receiving etretinate, the lag-time i.e. the time elapsing until appearance of first-order drug absorption was 1.24 +/- 0.27 for the parent drug and 0.69 hrs +/- 0.16 (mean value +/- S.D.) for its metabolite, etretin.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),,1.24,157321,DB00755,Tretinoin
,2959917,lag-time,"In patients receiving etretinate, the lag-time i.e. the time elapsing until appearance of first-order drug absorption was 1.24 +/- 0.27 for the parent drug and 0.69 hrs +/- 0.16 (mean value +/- S.D.) for its metabolite, etretin.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,0.69,157322,DB00755,Tretinoin
,2959917,time elapsing until appearance of first-order drug absorption,"In patients receiving etretinate, the lag-time i.e. the time elapsing until appearance of first-order drug absorption was 1.24 +/- 0.27 for the parent drug and 0.69 hrs +/- 0.16 (mean value +/- S.D.) for its metabolite, etretin.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),,1.24,157323,DB00755,Tretinoin
,2959917,time elapsing until appearance of first-order drug absorption,"In patients receiving etretinate, the lag-time i.e. the time elapsing until appearance of first-order drug absorption was 1.24 +/- 0.27 for the parent drug and 0.69 hrs +/- 0.16 (mean value +/- S.D.) for its metabolite, etretin.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,0.69,157324,DB00755,Tretinoin
,2959917,Absorption half-times,"Absorption half-times were 0.86 +/- 0.04 and 0.55 hrs +/- 0.09, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,0.86,157325,DB00755,Tretinoin
,2959917,Absorption half-times,"Absorption half-times were 0.86 +/- 0.04 and 0.55 hrs +/- 0.09, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,0.55,157326,DB00755,Tretinoin
,2959917,lag-time,The patients receiving etretin showed a lag-time of 0.42 hrs +/- 0.23 and an absorption half-time of 0.33 hrs +/- 0.28.,Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,0.42,157327,DB00755,Tretinoin
,2959917,absorption half-time,The patients receiving etretin showed a lag-time of 0.42 hrs +/- 0.23 and an absorption half-time of 0.33 hrs +/- 0.28.,Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,0.33,157328,DB00755,Tretinoin
,2959917,half-times,"The mean half-times of the distributory phases of disposition for etretinate and etretin were about 1 and 1.3 hrs and the apparent terminal half-lives were 6.57 +/- 2.09 and 5.52 hrs +/- 1.76, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,1,157329,DB00755,Tretinoin
,2959917,half-times,"The mean half-times of the distributory phases of disposition for etretinate and etretin were about 1 and 1.3 hrs and the apparent terminal half-lives were 6.57 +/- 2.09 and 5.52 hrs +/- 1.76, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,1.3,157330,DB00755,Tretinoin
,2959917,apparent terminal half-lives,"The mean half-times of the distributory phases of disposition for etretinate and etretin were about 1 and 1.3 hrs and the apparent terminal half-lives were 6.57 +/- 2.09 and 5.52 hrs +/- 1.76, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,6.57,157331,DB00755,Tretinoin
,2959917,apparent terminal half-lives,"The mean half-times of the distributory phases of disposition for etretinate and etretin were about 1 and 1.3 hrs and the apparent terminal half-lives were 6.57 +/- 2.09 and 5.52 hrs +/- 1.76, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,5.52,157332,DB00755,Tretinoin
,2959917,apparent volumes of distributions,"Assuming 40% systemic availability for both drugs the mean apparent volumes of distributions were calculated to be 1.50 +/- 0.46 and 1.31 l X kg-1 +/- 0.53 and mean plasma clearances were 177.8 +/- 105.8 and 175.9 ml X kg-1 X hr-1 +/- 81.4 for etretinate and etretin, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),[l] / [kg],1.50,157333,DB00755,Tretinoin
,2959917,apparent volumes of distributions,"Assuming 40% systemic availability for both drugs the mean apparent volumes of distributions were calculated to be 1.50 +/- 0.46 and 1.31 l X kg-1 +/- 0.53 and mean plasma clearances were 177.8 +/- 105.8 and 175.9 ml X kg-1 X hr-1 +/- 81.4 for etretinate and etretin, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),[l] / [kg],1.31,157334,DB00755,Tretinoin
,2959917,plasma clearances,"Assuming 40% systemic availability for both drugs the mean apparent volumes of distributions were calculated to be 1.50 +/- 0.46 and 1.31 l X kg-1 +/- 0.53 and mean plasma clearances were 177.8 +/- 105.8 and 175.9 ml X kg-1 X hr-1 +/- 81.4 for etretinate and etretin, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),[ml] / [h·kg],177.8,157335,DB00755,Tretinoin
,2959917,plasma clearances,"Assuming 40% systemic availability for both drugs the mean apparent volumes of distributions were calculated to be 1.50 +/- 0.46 and 1.31 l X kg-1 +/- 0.53 and mean plasma clearances were 177.8 +/- 105.8 and 175.9 ml X kg-1 X hr-1 +/- 81.4 for etretinate and etretin, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),[ml] / [h·kg],175.9,157336,DB00755,Tretinoin
,18370515,area under the plasma concentration-time curve (AUC),"Body systemic exposure to tretinoin as determined by the area under the plasma concentration-time curve (AUC) decreased significantly during the first week of drug administration, from (mean +/- SD) 678.3 +/- 498.1 to 258.7 +/- 272.4 microg/L.h.",Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370515/),[μg] / [h·l],678.3,157464,DB00755,Tretinoin
,18370515,area under the plasma concentration-time curve (AUC),"Body systemic exposure to tretinoin as determined by the area under the plasma concentration-time curve (AUC) decreased significantly during the first week of drug administration, from (mean +/- SD) 678.3 +/- 498.1 to 258.7 +/- 272.4 microg/L.h.",Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370515/),[μg] / [h·l],258.7,157465,DB00755,Tretinoin
,2634535,peak concentration,"The results showed that peak concentration of RII in plasma appeared at 8 hrs after oral administration of 200 mg of the drug, and the mean peak concentration in serum was 3.612 +/- 1.099 micrograms/ml.",[Pharmacokinetic study of 4-(hydroxycarbophenyl) retinamide (RII) in cancer patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2634535/),[μg] / [ml],3.612,166249,DB00755,Tretinoin
,2634535,Half life time (T1/2),Half life time (T1/2) was 6.62 +/- 0.81 hrs.,[Pharmacokinetic study of 4-(hydroxycarbophenyl) retinamide (RII) in cancer patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2634535/),h,6.62,166250,DB00755,Tretinoin
,2634535,area under the drug-time curve (AUC),The area under the drug-time curve (AUC) was 35.70 +/- 14.46 micrograms hr/ml.,[Pharmacokinetic study of 4-(hydroxycarbophenyl) retinamide (RII) in cancer patients]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2634535/),[h·μg] / [ml],35.70,166251,DB00755,Tretinoin
,15881775,Drug loading,"Drug loading was 3.3%, drug entrapment efficiency was more than 95%, the in vitro release was well in accordance with Weibull distribution.",[Preparation of solid lipid nanoparticles loaded with all-trans retinoic acid and their evaluation in vitro and in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881775/),%,3.3,177423,DB00755,Tretinoin
,32067249,terminal half-life,AZD0284 was absorbed rapidly into plasma after oral dosing and exhibited a terminal half-life of 13-16 hours.,"Pharmacokinetics, pharmacodynamics and safety of the inverse retinoic acid-related orphan receptor γ agonist AZD0284. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32067249/),h,13-16,177962,DB00755,Tretinoin
,7756637,terminal plasma half-life,"Pharmacokinetic studies showed that the mean terminal plasma half-life of 9-cis RA (1.3 hours) changed very little after several weeks of dosing, although the mean change per dose level in area under the plasma concentration x time curves and peak plasma concentrations showed a decrease by 49% and 45%, respectively.",9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756637/),h,1.3,179104,DB00755,Tretinoin
,2533684,Absorption lag-times,"Absorption lag-times ranged from 0.3-2.5 hr, whereas the apparent absorption first order half-times (t1/2ka) were within the range of 0.3-1.2 hr.",Pharmacokinetics of etretinate in psoriatic patients with liver fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533684/),h,0.3-2.5,183394,DB00755,Tretinoin
,2533684,apparent absorption first order half-times (t1/2ka),"Absorption lag-times ranged from 0.3-2.5 hr, whereas the apparent absorption first order half-times (t1/2ka) were within the range of 0.3-1.2 hr.",Pharmacokinetics of etretinate in psoriatic patients with liver fibrosis. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533684/),h,0.3-1.2,183395,DB00755,Tretinoin
,15380716,flow rate,"A mobile phase composed of ammonium acetate (0.1 M), acetic acid solution (2% (v/v)) and methanol at a flow rate of 1.0 mL/min was used for gradient elution.","Quantification of a novel retinoic acid metabolism inhibitor, 4-(1H-imidazol-1-yl)retinoic acid (VN/14-1RA) and other retinoids in rat plasma by liquid chromatography with diode-array detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380716/),[ml] / [min],1.0,191560,DB00755,Tretinoin
,15380716,recoveries,The recoveries for all compounds ranged from 65 to 85% regardless of the concentrations examined.,"Quantification of a novel retinoic acid metabolism inhibitor, 4-(1H-imidazol-1-yl)retinoic acid (VN/14-1RA) and other retinoids in rat plasma by liquid chromatography with diode-array detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380716/),%,65 to 85,191561,DB00755,Tretinoin
,15380716,terminal elimination half-life (t(1/2)),The mean terminal elimination half-life (t(1/2)) was 19.0 +/- 3.2 min.,"Quantification of a novel retinoic acid metabolism inhibitor, 4-(1H-imidazol-1-yl)retinoic acid (VN/14-1RA) and other retinoids in rat plasma by liquid chromatography with diode-array detection. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380716/),min,19.0,191562,DB00755,Tretinoin
up to,2967472,elimination half-life,"Hitherto, the use of the carboxylic acid ester analogue, etretinate, has been hampered by an extremely long elimination half-life of up to 120 days for this drug.",Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967472/),d,120,191751,DB00755,Tretinoin
,2967472,t 1/2 beta,"Etretin as drug was eliminated faster than the metabolite etretin, t 1/2 beta 2.39 +/- 1.16 days compared to 6.51 +/- 2.06 days.",Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967472/),d,2.39,191752,DB00755,Tretinoin
,2967472,t 1/2 beta,"Etretin as drug was eliminated faster than the metabolite etretin, t 1/2 beta 2.39 +/- 1.16 days compared to 6.51 +/- 2.06 days.",Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967472/),d,6.51,191753,DB00755,Tretinoin
,2967472,t 1/2 lambda,In patients receiving etretinate the terminal disposition or elimination half-lives for cisetretin (t 1/2 lambda 3 15.9 +/- 9.9 days) were longer than for the metabolite etretin and exhibit a pronounced interindividual variation from 4.25 to 22.8 days.,Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967472/),d,15.9,191754,DB00755,Tretinoin
,2967472,central compartment of distribution,"Assuming 40% systemic availability for both drugs, the central compartment of distribution constituted about 12-32% in case of etretin and about 0.8-3.6% in case of etretinate of the calculated apparent total volume of distribution at steady state, which showed mean values of 3.5 and 39.6 1.kg.-1, respectively, presumably reflecting the higher lipophilic nature of the latter compound.",Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967472/),%,12-32,191755,DB00755,Tretinoin
,2967472,central compartment of distribution,"Assuming 40% systemic availability for both drugs, the central compartment of distribution constituted about 12-32% in case of etretin and about 0.8-3.6% in case of etretinate of the calculated apparent total volume of distribution at steady state, which showed mean values of 3.5 and 39.6 1.kg.-1, respectively, presumably reflecting the higher lipophilic nature of the latter compound.",Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967472/),%,0.8-3.6,191756,DB00755,Tretinoin
,2967472,apparent total volume of distribution at steady state,"Assuming 40% systemic availability for both drugs, the central compartment of distribution constituted about 12-32% in case of etretin and about 0.8-3.6% in case of etretinate of the calculated apparent total volume of distribution at steady state, which showed mean values of 3.5 and 39.6 1.kg.-1, respectively, presumably reflecting the higher lipophilic nature of the latter compound.",Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967472/),-1·1·kg,3.5,191757,DB00755,Tretinoin
,2967472,apparent total volume of distribution at steady state,"Assuming 40% systemic availability for both drugs, the central compartment of distribution constituted about 12-32% in case of etretin and about 0.8-3.6% in case of etretinate of the calculated apparent total volume of distribution at steady state, which showed mean values of 3.5 and 39.6 1.kg.-1, respectively, presumably reflecting the higher lipophilic nature of the latter compound.",Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967472/),-1·1·kg,39.6,191758,DB00755,Tretinoin
,8713573,peak plasma concentration,A pharmacokinetic study revealed that the mean peak plasma concentration was 208 ng/ml and was reached at 150 min after ingestion.,Pharmacokinetics of all-trans-retinoic acid in Japanese patients with acute promyelocytic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8713573/),[ng] / [ml],208,192077,DB00755,Tretinoin
,8713573,area under the concentration x time curve (AUC),The mean area under the concentration x time curve (AUC) was 498 ng.h/ml.,Pharmacokinetics of all-trans-retinoic acid in Japanese patients with acute promyelocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8713573/),[h·ng] / [ml],498,192078,DB00755,Tretinoin
,7834612,half-life,"The plasma drug concentration profile of 9-cis-retinoic acid was consistent with a first-order elimination process, with a harmonic mean half-life of 31 min, and a mean clearance of 97 ml/min/m2.",Pharmacokinetics of 9-cis-retinoic acid in the rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834612/),min,31,192696,DB00755,Tretinoin
,7834612,clearance,"The plasma drug concentration profile of 9-cis-retinoic acid was consistent with a first-order elimination process, with a harmonic mean half-life of 31 min, and a mean clearance of 97 ml/min/m2.",Pharmacokinetics of 9-cis-retinoic acid in the rhesus monkey. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834612/),[ml] / [m2·min],97,192697,DB00755,Tretinoin
up to,1828811,elimination half-life,"Hitherto, the use of the carboxylic acid ester analogue, etretinate, has been hampered by an extremely long elimination half-life of up to 120 days for this drug.",The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1828811/),d,120,196045,DB00755,Tretinoin
,1828811,apparent absorption half-life,The maximum plasma concentration of the drug occurred within about 0.9 to 4.6 hours with an apparent absorption half-life ranging from 0.2 to 1.7 hours and with half-lives of the distribution phase within the range of 1.2 to 3.5 hours.,The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1828811/),h,0.2 to 1.7,196046,DB00755,Tretinoin
,1828811,half-lives of the distribution phase,The maximum plasma concentration of the drug occurred within about 0.9 to 4.6 hours with an apparent absorption half-life ranging from 0.2 to 1.7 hours and with half-lives of the distribution phase within the range of 1.2 to 3.5 hours.,The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1828811/),h,1.2 to 3.5,196047,DB00755,Tretinoin
,1828811,terminal elimination half-life,"After stopping therapy, the terminal elimination half-life of acitretin varied between 16.5 and 111.1 hours (mean: 47.1 hr +/- 29.8 SD), whereas that for the 13-cis-metabolite varied between 36.5 and 249.4 hours (mean: 119.4 hr +/- 73.4 SD).",The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1828811/),h,16.5 and 111.1,196048,DB00755,Tretinoin
,1828811,terminal elimination half-life,"After stopping therapy, the terminal elimination half-life of acitretin varied between 16.5 and 111.1 hours (mean: 47.1 hr +/- 29.8 SD), whereas that for the 13-cis-metabolite varied between 36.5 and 249.4 hours (mean: 119.4 hr +/- 73.4 SD).",The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1828811/),h,47.1,196049,DB00755,Tretinoin
,1828811,terminal elimination half-life,"After stopping therapy, the terminal elimination half-life of acitretin varied between 16.5 and 111.1 hours (mean: 47.1 hr +/- 29.8 SD), whereas that for the 13-cis-metabolite varied between 36.5 and 249.4 hours (mean: 119.4 hr +/- 73.4 SD).",The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1828811/),h,36.5 and 249.4,196050,DB00755,Tretinoin
,1828811,terminal elimination half-life,"After stopping therapy, the terminal elimination half-life of acitretin varied between 16.5 and 111.1 hours (mean: 47.1 hr +/- 29.8 SD), whereas that for the 13-cis-metabolite varied between 36.5 and 249.4 hours (mean: 119.4 hr +/- 73.4 SD).",The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1828811/),h,119.4,196051,DB00755,Tretinoin
,10640519,peak concentration,"All-trans retinoic acid permeated well into the WM, giving peak concentration in WM of 25.7 microg/g, 6 to 7 times higher than the peak serum concentration.","Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640519/),[μg] / [g],25.7,197391,DB00755,Tretinoin
,10640519,area under the curve (AUC)(0-->infinity),There was less 13-cis retinoic acid in WM: area under the curve (AUC)(0-->infinity) WM/AUC(0-->infinity) serum = 18.00 microg ml(-1) h/32.67 microg ml(-1) h.,"Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640519/),[h·μg] / [ml],18.00,197392,DB00755,Tretinoin
,10640519,AUC(0-->infinity) serum,There was less 13-cis retinoic acid in WM: area under the curve (AUC)(0-->infinity) WM/AUC(0-->infinity) serum = 18.00 microg ml(-1) h/32.67 microg ml(-1) h.,"Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640519/),[h·μg] / [ml],18.00,197393,DB00755,Tretinoin
,10640519,AUC(0-->infinity) serum,There was less 13-cis retinoic acid in WM: area under the curve (AUC)(0-->infinity) WM/AUC(0-->infinity) serum = 18.00 microg ml(-1) h/32.67 microg ml(-1) h.,"Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640519/),[h·μg] / [ml],32.67,197394,DB00755,Tretinoin
over,10640519,ratio,"The ratio WM/GM was over 1 for these two compounds, but the half-lives were short in the serum and cerebral tissue (0.57-1.02 h).","Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640519/),,1,197395,DB00755,Tretinoin
,10640519,half-lives,"The ratio WM/GM was over 1 for these two compounds, but the half-lives were short in the serum and cerebral tissue (0.57-1.02 h).","Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640519/),h,0.57-1.02,197396,DB00755,Tretinoin
,10640519,peak concentrations,"Fenretinide had different pharmacokinetics: the peak concentrations were in serum (1.7 microg/ml) and WM (1.2 microg/ml)-low, but the AUC(0-->infinity) was large (25.55 microg ml(-1) in serum and 57.53 microg ml(-1) in WM) due to its long elimination half-life (13.78 h in serum and 17.77 h in WM).","Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640519/),[μg] / [ml],1.7,197397,DB00755,Tretinoin
,10640519,peak concentrations,"Fenretinide had different pharmacokinetics: the peak concentrations were in serum (1.7 microg/ml) and WM (1.2 microg/ml)-low, but the AUC(0-->infinity) was large (25.55 microg ml(-1) in serum and 57.53 microg ml(-1) in WM) due to its long elimination half-life (13.78 h in serum and 17.77 h in WM).","Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640519/),[μg] / [ml],1.2,197398,DB00755,Tretinoin
,10640519,AUC(0-->infinity),"Fenretinide had different pharmacokinetics: the peak concentrations were in serum (1.7 microg/ml) and WM (1.2 microg/ml)-low, but the AUC(0-->infinity) was large (25.55 microg ml(-1) in serum and 57.53 microg ml(-1) in WM) due to its long elimination half-life (13.78 h in serum and 17.77 h in WM).","Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640519/),[μg] / [ml],25.55,197399,DB00755,Tretinoin
,10640519,AUC(0-->infinity),"Fenretinide had different pharmacokinetics: the peak concentrations were in serum (1.7 microg/ml) and WM (1.2 microg/ml)-low, but the AUC(0-->infinity) was large (25.55 microg ml(-1) in serum and 57.53 microg ml(-1) in WM) due to its long elimination half-life (13.78 h in serum and 17.77 h in WM).","Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640519/),[μg] / [ml],57.53,197400,DB00755,Tretinoin
,10640519,elimination half-life,"Fenretinide had different pharmacokinetics: the peak concentrations were in serum (1.7 microg/ml) and WM (1.2 microg/ml)-low, but the AUC(0-->infinity) was large (25.55 microg ml(-1) in serum and 57.53 microg ml(-1) in WM) due to its long elimination half-life (13.78 h in serum and 17.77 h in WM).","Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640519/),h,13.78,197401,DB00755,Tretinoin
,10640519,elimination half-life,"Fenretinide had different pharmacokinetics: the peak concentrations were in serum (1.7 microg/ml) and WM (1.2 microg/ml)-low, but the AUC(0-->infinity) was large (25.55 microg ml(-1) in serum and 57.53 microg ml(-1) in WM) due to its long elimination half-life (13.78 h in serum and 17.77 h in WM).","Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640519/),h,17.77,197402,DB00755,Tretinoin
,12855611,tissue:plasma retinamide ratios,The highest mean tissue:plasma retinamide ratios were achieved at 200 mg/day: 639.5 +/- 253.8 to 190.6 +/- 91.9 ng/ml (4.8:1) for 4-HPR and 594.4 +/- 201.9 to 130.5 +/- 37.8 ng/ml (6.6:1) for 4-MPR.,Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12855611/),[ng] / [ml],639.5,199198,DB00755,Tretinoin
,12855611,tissue:plasma retinamide ratios,The highest mean tissue:plasma retinamide ratios were achieved at 200 mg/day: 639.5 +/- 253.8 to 190.6 +/- 91.9 ng/ml (4.8:1) for 4-HPR and 594.4 +/- 201.9 to 130.5 +/- 37.8 ng/ml (6.6:1) for 4-MPR.,Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12855611/),[ng] / [ml],190.6,199199,DB00755,Tretinoin
,12855611,tissue:plasma retinamide ratios,The highest mean tissue:plasma retinamide ratios were achieved at 200 mg/day: 639.5 +/- 253.8 to 190.6 +/- 91.9 ng/ml (4.8:1) for 4-HPR and 594.4 +/- 201.9 to 130.5 +/- 37.8 ng/ml (6.6:1) for 4-MPR.,Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12855611/),[ng] / [ml],594.4,199200,DB00755,Tretinoin
,12855611,tissue:plasma retinamide ratios,The highest mean tissue:plasma retinamide ratios were achieved at 200 mg/day: 639.5 +/- 253.8 to 190.6 +/- 91.9 ng/ml (4.8:1) for 4-HPR and 594.4 +/- 201.9 to 130.5 +/- 37.8 ng/ml (6.6:1) for 4-MPR.,Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12855611/),[ng] / [ml],130.5,199201,DB00755,Tretinoin
,10374268,maximal plasma concentration,The results showed that maximal plasma concentration with oral ATRA at 15 mg/m2 was high enough (10(-6) mol/L) to induce APL cell differentiation.,[Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10374268/),[mol] / [l],10(-6),204953,DB00755,Tretinoin
,9243349,half-life,The half-life was in the range of 1.3 to 2.4 hours.,Pharmacokinetics and pharmacodynamics of 9-cis-retinoic acid in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243349/),h,1.3 to 2.4,204972,DB00755,Tretinoin
,7736916,maximal velocity of elimination,"Fitting the data to a three-compartment model with saturable absorption and elimination kinetics confirmed the autoinduction of RA elimination (maximal velocity of elimination = 3330 vs. 541 micrograms/hr, p = 0.006, MM constant KMe = 7.53 vs. 1.10 micrograms/ml, p = 0.006) after 12 days RA administration, and an MM absorption mechanism resulting in a saturable absorption (bioavailability F = 0.58 at 2 mg vs. 0.25 at 5 mg, group 3) that decreased after 12 days of RA treatment: the maximal velocity of absorption decreased from 1632 (group 3) to 631 micrograms/hr (group 4) (p = 0.02).",Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736916/),[μg] / [h],3330,205453,DB00755,Tretinoin
,7736916,maximal velocity of elimination,"Fitting the data to a three-compartment model with saturable absorption and elimination kinetics confirmed the autoinduction of RA elimination (maximal velocity of elimination = 3330 vs. 541 micrograms/hr, p = 0.006, MM constant KMe = 7.53 vs. 1.10 micrograms/ml, p = 0.006) after 12 days RA administration, and an MM absorption mechanism resulting in a saturable absorption (bioavailability F = 0.58 at 2 mg vs. 0.25 at 5 mg, group 3) that decreased after 12 days of RA treatment: the maximal velocity of absorption decreased from 1632 (group 3) to 631 micrograms/hr (group 4) (p = 0.02).",Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736916/),[μg] / [h],541,205454,DB00755,Tretinoin
,7736916,constant KMe,"Fitting the data to a three-compartment model with saturable absorption and elimination kinetics confirmed the autoinduction of RA elimination (maximal velocity of elimination = 3330 vs. 541 micrograms/hr, p = 0.006, MM constant KMe = 7.53 vs. 1.10 micrograms/ml, p = 0.006) after 12 days RA administration, and an MM absorption mechanism resulting in a saturable absorption (bioavailability F = 0.58 at 2 mg vs. 0.25 at 5 mg, group 3) that decreased after 12 days of RA treatment: the maximal velocity of absorption decreased from 1632 (group 3) to 631 micrograms/hr (group 4) (p = 0.02).",Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736916/),[μg] / [ml],7.53,205455,DB00755,Tretinoin
,7736916,constant KMe,"Fitting the data to a three-compartment model with saturable absorption and elimination kinetics confirmed the autoinduction of RA elimination (maximal velocity of elimination = 3330 vs. 541 micrograms/hr, p = 0.006, MM constant KMe = 7.53 vs. 1.10 micrograms/ml, p = 0.006) after 12 days RA administration, and an MM absorption mechanism resulting in a saturable absorption (bioavailability F = 0.58 at 2 mg vs. 0.25 at 5 mg, group 3) that decreased after 12 days of RA treatment: the maximal velocity of absorption decreased from 1632 (group 3) to 631 micrograms/hr (group 4) (p = 0.02).",Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736916/),[μg] / [ml],1.10,205456,DB00755,Tretinoin
,7736916,bioavailability F,"Fitting the data to a three-compartment model with saturable absorption and elimination kinetics confirmed the autoinduction of RA elimination (maximal velocity of elimination = 3330 vs. 541 micrograms/hr, p = 0.006, MM constant KMe = 7.53 vs. 1.10 micrograms/ml, p = 0.006) after 12 days RA administration, and an MM absorption mechanism resulting in a saturable absorption (bioavailability F = 0.58 at 2 mg vs. 0.25 at 5 mg, group 3) that decreased after 12 days of RA treatment: the maximal velocity of absorption decreased from 1632 (group 3) to 631 micrograms/hr (group 4) (p = 0.02).",Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736916/),,0.58,205457,DB00755,Tretinoin
,7736916,bioavailability F,"Fitting the data to a three-compartment model with saturable absorption and elimination kinetics confirmed the autoinduction of RA elimination (maximal velocity of elimination = 3330 vs. 541 micrograms/hr, p = 0.006, MM constant KMe = 7.53 vs. 1.10 micrograms/ml, p = 0.006) after 12 days RA administration, and an MM absorption mechanism resulting in a saturable absorption (bioavailability F = 0.58 at 2 mg vs. 0.25 at 5 mg, group 3) that decreased after 12 days of RA treatment: the maximal velocity of absorption decreased from 1632 (group 3) to 631 micrograms/hr (group 4) (p = 0.02).",Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736916/),,0.25,205458,DB00755,Tretinoin
,7736916,maximal velocity of absorption,"Fitting the data to a three-compartment model with saturable absorption and elimination kinetics confirmed the autoinduction of RA elimination (maximal velocity of elimination = 3330 vs. 541 micrograms/hr, p = 0.006, MM constant KMe = 7.53 vs. 1.10 micrograms/ml, p = 0.006) after 12 days RA administration, and an MM absorption mechanism resulting in a saturable absorption (bioavailability F = 0.58 at 2 mg vs. 0.25 at 5 mg, group 3) that decreased after 12 days of RA treatment: the maximal velocity of absorption decreased from 1632 (group 3) to 631 micrograms/hr (group 4) (p = 0.02).",Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736916/),[μg] / [h],1632,205459,DB00755,Tretinoin
,7736916,maximal velocity of absorption,"Fitting the data to a three-compartment model with saturable absorption and elimination kinetics confirmed the autoinduction of RA elimination (maximal velocity of elimination = 3330 vs. 541 micrograms/hr, p = 0.006, MM constant KMe = 7.53 vs. 1.10 micrograms/ml, p = 0.006) after 12 days RA administration, and an MM absorption mechanism resulting in a saturable absorption (bioavailability F = 0.58 at 2 mg vs. 0.25 at 5 mg, group 3) that decreased after 12 days of RA treatment: the maximal velocity of absorption decreased from 1632 (group 3) to 631 micrograms/hr (group 4) (p = 0.02).",Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736916/),[μg] / [h],631,205460,DB00755,Tretinoin
,7736916,volume of distribution,"The volume of distribution also decreased after pretreatment, which indicated a modification in tissular distribution (565 vs. 358 ml, p < 0.001, group 3 vs. 4).",Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736916/),ml,565,205461,DB00755,Tretinoin
,7736916,volume of distribution,"The volume of distribution also decreased after pretreatment, which indicated a modification in tissular distribution (565 vs. 358 ml, p < 0.001, group 3 vs. 4).",Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736916/),ml,358,205462,DB00755,Tretinoin
,7736916,t,"The volume of distribution also decreased after pretreatment, which indicated a modification in tissular distribution (565 vs. 358 ml, p < 0.001, group 3 vs. 4).",Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736916/),ml,565,205463,DB00755,Tretinoin
,7736916,t,"The volume of distribution also decreased after pretreatment, which indicated a modification in tissular distribution (565 vs. 358 ml, p < 0.001, group 3 vs. 4).",Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736916/),ml,358,205464,DB00755,Tretinoin
> or =,9025769,initial peak [ATRA],"Severe toxicities tended to occur with initial peak [ATRA] of > or = 0.5 microgram/ml (1.7 microM), and the toxicity frequency did not change if [ATRA] decreased with continued dosing.",Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9025769/),[μg] / [ml],0.5,206767,DB00755,Tretinoin
,9025769,initial peak [ATRA],"Severe toxicities tended to occur with initial peak [ATRA] of > or = 0.5 microgram/ml (1.7 microM), and the toxicity frequency did not change if [ATRA] decreased with continued dosing.",Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9025769/),μM,1.7,206768,DB00755,Tretinoin
,9807973,elimination half-life (t1/2),"Values for elimination half-life (t1/2) of isotretinoin and its metabolite were 29+/-40 hours and 22+/-10 hours, respectively.",Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: implications for fetal safety. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9807973/),h,29,207783,DB00755,Tretinoin
,9807973,elimination half-life (t1/2),"Values for elimination half-life (t1/2) of isotretinoin and its metabolite were 29+/-40 hours and 22+/-10 hours, respectively.",Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: implications for fetal safety. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9807973/),h,22,207784,DB00755,Tretinoin
,8656678,maximal plasma concentration (Cpmax),The results showed that maximal plasma concentration (Cpmax) with oral 15 mg/m2 ATRA was high enough (10(-6) M) to induce APL cell differentiation.,Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8656678/),M,10(-6),211278,DB00755,Tretinoin
up to,29162478,loading efficiency,The Di-ATRA-PC assembled liposomes were prepared by thin film hydration method with ATRA loading efficiency up to 73wt%.,Liposomes assembled from dimeric retinoic acid phospholipid with improved pharmacokinetic properties. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162478/),w,73,212151,DB00755,Tretinoin
,8069549,log PCoct,"3H-Retinoic acid and 14C-cholesteryl oleate with different lipophilicities (log PCoct = 6.6 and 18, respectively) were selected as model drugs and the potential of formulations such as oil in water (o/w) emulsion, micellar solution, and liposomes for controlling their biodistribution was demonstrated.",Controlled biodistribution of highly lipophilic drugs with various parenteral formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8069549/),,6.6,213487,DB00755,Tretinoin
,8069549,log PCoct,"3H-Retinoic acid and 14C-cholesteryl oleate with different lipophilicities (log PCoct = 6.6 and 18, respectively) were selected as model drugs and the potential of formulations such as oil in water (o/w) emulsion, micellar solution, and liposomes for controlling their biodistribution was demonstrated.",Controlled biodistribution of highly lipophilic drugs with various parenteral formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8069549/),,18,213488,DB00755,Tretinoin
,3978647,peak plasma level,"At 200 mg/sq m, the mean peak plasma level of 13-cis-RA was 1.5 +/- 0.1 (SE) micrograms/ml; at 400 mg/sq m, the mean peak plasma level increased to 3.8 +/- 0.7 micrograms/ml.",Phase I study and pharmacokinetics of weekly high-dose 13-cis-retinoic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978647/),[μg] / [ml],1.5,217080,DB00755,Tretinoin
,3978647,peak plasma level,"At 200 mg/sq m, the mean peak plasma level of 13-cis-RA was 1.5 +/- 0.1 (SE) micrograms/ml; at 400 mg/sq m, the mean peak plasma level increased to 3.8 +/- 0.7 micrograms/ml.",Phase I study and pharmacokinetics of weekly high-dose 13-cis-retinoic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978647/),[μg] / [ml],3.8,217081,DB00755,Tretinoin
,3978647,terminal half-life,"The terminal half-life was highly variable (range, 2.8 to 101.3 h) and was not related to the dose given.",Phase I study and pharmacokinetics of weekly high-dose 13-cis-retinoic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978647/),h,2.8 to 101.3,217082,DB00755,Tretinoin
,2522404,absolute bioavailability,The mean absolute bioavailability of acitretin is 59% with high interpatient variability consistent with that of etretinate.,"Overview of recent clinical pharmacokinetic studies with acitretin (Ro 10-1670, etretin). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2522404/),%,59,218598,DB00755,Tretinoin
,2522404,elimination half-life,The drug appears to be extensively distributed throughout the body without unexpected accumulation and the elimination half-life is approximately 50 h.,"Overview of recent clinical pharmacokinetic studies with acitretin (Ro 10-1670, etretin). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2522404/),h,50,218599,DB00755,Tretinoin
,11747346,bioavailability,The bioavailability of 9-cis RA in rat was 11% and the elimination half-life (t1/2) was 35 min.,Bioavailability and dose-dependent anti-tumour effects of 9-cis retinoic acid on human neuroblastoma xenografts in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11747346/),%,11,219115,DB00755,Tretinoin
,11747346,elimination half-life (t1/2),The bioavailability of 9-cis RA in rat was 11% and the elimination half-life (t1/2) was 35 min.,Bioavailability and dose-dependent anti-tumour effects of 9-cis retinoic acid on human neuroblastoma xenografts in rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11747346/),min,35,219116,DB00755,Tretinoin
,7575674,area under the plasma trans-retinoic acid concentration vs time curve,"Treatment with trans-retinoic acid for 1 week reduced the area under the plasma trans-retinoic acid concentration vs time curve in one patient by 67%, from 277 to 91 ng/mL/hr.",Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575674/),[ng] / [h·ml],277,221994,DB00755,Tretinoin
,7575674,area under the plasma trans-retinoic acid concentration vs time curve,"Treatment with trans-retinoic acid for 1 week reduced the area under the plasma trans-retinoic acid concentration vs time curve in one patient by 67%, from 277 to 91 ng/mL/hr.",Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575674/),[ng] / [h·ml],91,221995,DB00755,Tretinoin
,7575674,AUC,"Trans-retinoic acid pharmacokinetics were repeated after the second dose of fluconazole, administered 1 hour prior to the retinoid, and the AUC was found to be 401 ng/mL/hr, a greater than 4-fold increase from the pre-fluconazole level.",Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575674/),[ng] / [h·ml],401,221996,DB00755,Tretinoin
,11745761,volume of distribution at the steady state (V(ss)),"However, as the dose increased from 5 micromol/kg to 10 micromol/kg, the volume of distribution at the steady state (V(ss)) and the volume of peripheral compartment (V(p)) decreased significantly (p < 0.05) from 1.290 +/- 0.269, 0.928 +/- 0.232. L/kg to 0.961 +/- 0.149, 0.647 +/- 0.107 L/kg, respectively.",Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745761/),[l] / [kg],1.290,223285,DB00755,Tretinoin
,11745761,volume of peripheral compartment (V(p)),"However, as the dose increased from 5 micromol/kg to 10 micromol/kg, the volume of distribution at the steady state (V(ss)) and the volume of peripheral compartment (V(p)) decreased significantly (p < 0.05) from 1.290 +/- 0.269, 0.928 +/- 0.232. L/kg to 0.961 +/- 0.149, 0.647 +/- 0.107 L/kg, respectively.",Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s). ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745761/),[l] / [kg],0.928,223286,DB00755,Tretinoin
,11745761,volume of peripheral compartment (V(p)),"However, as the dose increased from 5 micromol/kg to 10 micromol/kg, the volume of distribution at the steady state (V(ss)) and the volume of peripheral compartment (V(p)) decreased significantly (p < 0.05) from 1.290 +/- 0.269, 0.928 +/- 0.232. L/kg to 0.961 +/- 0.149, 0.647 +/- 0.107 L/kg, respectively.",Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s). ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745761/),[l] / [kg],0.961,223287,DB00755,Tretinoin
,11745761,volume of peripheral compartment (V(p)),"However, as the dose increased from 5 micromol/kg to 10 micromol/kg, the volume of distribution at the steady state (V(ss)) and the volume of peripheral compartment (V(p)) decreased significantly (p < 0.05) from 1.290 +/- 0.269, 0.928 +/- 0.232. L/kg to 0.961 +/- 0.149, 0.647 +/- 0.107 L/kg, respectively.",Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s). ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745761/),[l] / [kg],0.647,223288,DB00755,Tretinoin
,11745761,V(ss),"V(ss) and V(p) at a dose of 15 micromol/kg (0.924 +/- 0.187, 0.698 +/- 0.165 L/kg) were not significantly different from that at 10 micromol/kg.",Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745761/),[l] / [kg],0.924,223289,DB00755,Tretinoin
,11745761,V(p),"V(ss) and V(p) at a dose of 15 micromol/kg (0.924 +/- 0.187, 0.698 +/- 0.165 L/kg) were not significantly different from that at 10 micromol/kg.",Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745761/),[l] / [kg],0.698,223290,DB00755,Tretinoin
,11745761,K(12),"However, K(12), V(p), and V(ss) declined significantly (p < 0.05) from 1.67 +/- 0.54 h(-1), 0.928 +/- 0.232 L/kg, and 1.290 +/- 0.269 L/kg to 0.96 +/- 0.48 h(-1), 0.494 +/- 0.147 L/kg, and 0.818 +/- 0.187 L/kg, respectively.",Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s). ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745761/),1/[h],1.67,223291,DB00755,Tretinoin
,11745761,V(p),"However, K(12), V(p), and V(ss) declined significantly (p < 0.05) from 1.67 +/- 0.54 h(-1), 0.928 +/- 0.232 L/kg, and 1.290 +/- 0.269 L/kg to 0.96 +/- 0.48 h(-1), 0.494 +/- 0.147 L/kg, and 0.818 +/- 0.187 L/kg, respectively.",Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745761/),1/[h],0.96,223292,DB00755,Tretinoin
,11745761,V(p),"However, K(12), V(p), and V(ss) declined significantly (p < 0.05) from 1.67 +/- 0.54 h(-1), 0.928 +/- 0.232 L/kg, and 1.290 +/- 0.269 L/kg to 0.96 +/- 0.48 h(-1), 0.494 +/- 0.147 L/kg, and 0.818 +/- 0.187 L/kg, respectively.",Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745761/),[l] / [kg],0.494,223293,DB00755,Tretinoin
,11745761,V(ss),"However, K(12), V(p), and V(ss) declined significantly (p < 0.05) from 1.67 +/- 0.54 h(-1), 0.928 +/- 0.232 L/kg, and 1.290 +/- 0.269 L/kg to 0.96 +/- 0.48 h(-1), 0.494 +/- 0.147 L/kg, and 0.818 +/- 0.187 L/kg, respectively.",Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745761/),[l] / [kg],1.290,223294,DB00755,Tretinoin
,11745761,V(ss),"However, K(12), V(p), and V(ss) declined significantly (p < 0.05) from 1.67 +/- 0.54 h(-1), 0.928 +/- 0.232 L/kg, and 1.290 +/- 0.269 L/kg to 0.96 +/- 0.48 h(-1), 0.494 +/- 0.147 L/kg, and 0.818 +/- 0.187 L/kg, respectively.",Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745761/),[l] / [kg],0.818,223295,DB00755,Tretinoin
,11745761,AUC,"Although the AUC of RAG did not change significantly after multiple dosing, the AUC of ATRA after RAG dosing significantly declined (p < 0.05) from 0.032 +/- 0.019 microM x h to 0.010 +/- 0.006 microM x h.",Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745761/),h·μM,0.032,223296,DB00755,Tretinoin
,11745761,AUC,"Although the AUC of RAG did not change significantly after multiple dosing, the AUC of ATRA after RAG dosing significantly declined (p < 0.05) from 0.032 +/- 0.019 microM x h to 0.010 +/- 0.006 microM x h.",Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745761/),h·μM,0.010,223297,DB00755,Tretinoin
,7039822,detection limit,This assay system resulted in a clear separation of 13-CRA from all-trans-retinoic acid and retinol and had a detection limit of 20 ng/ml plasma.,Pharmacokinetics of 13-cis-retinoic acid in patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039822/),[ng] / [ml],20,224389,DB00755,Tretinoin
,7039822,Recovery,Recovery was 89 +/- 6% (S.D.) at equivalent physiological concentrations with a precision of 8%.,Pharmacokinetics of 13-cis-retinoic acid in patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039822/),%,89,224390,DB00755,Tretinoin
,7039822,time to peak plasma concentration,"For the 10 patients studied on the first day of 13-CRA administration, the mean time to peak plasma concentration was 222 +/- 102 min.",Pharmacokinetics of 13-cis-retinoic acid in patients with advanced cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039822/),min,222,224391,DB00755,Tretinoin
,7039822,Beta-Phase t 1/2,Beta-Phase t 1/2 was approximately 25 hr.,Pharmacokinetics of 13-cis-retinoic acid in patients with advanced cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039822/),h,25,224392,DB00755,Tretinoin
,8070324,plasma peak time,"Following a single initial oral administration of either isomer, the plasma peak time of 9-cis-RA (15-30 min) occurred earlier than that of tr-RA (60-180 min), but with lower plasma concentrations and area under the concentration-time curve (AUC) value.",Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070324/),min,15-30,229207,DB00755,Tretinoin
,8070324,plasma peak time,"Following a single initial oral administration of either isomer, the plasma peak time of 9-cis-RA (15-30 min) occurred earlier than that of tr-RA (60-180 min), but with lower plasma concentrations and area under the concentration-time curve (AUC) value.",Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070324/),min,60-180,229208,DB00755,Tretinoin
,17644497,flow rate,"Chromatographic separation was carried out on a Shimadzu VP-ODS column (250 mm x 2.0 mm, 5 microm) with a mobile phase of methanol-water (95:5, v/v) at a flow rate of 0.2 ml/min.",Development and validation of a LC-MS/MS method for the determination of viaminate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644497/),[ml] / [min],0.2,231472,DB00755,Tretinoin
,17644497,m/z,The corresponding parent ions were m/z 446 and m/z 345.,Development and validation of a LC-MS/MS method for the determination of viaminate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644497/),,446,231473,DB00755,Tretinoin
,17644497,m/z,The corresponding parent ions were m/z 446 and m/z 345.,Development and validation of a LC-MS/MS method for the determination of viaminate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644497/),,345,231474,DB00755,Tretinoin
,17644497,extraction-efficiency,"The extraction-efficiency at three concentrations was 100.7, 93.6, and 99.7%.",Development and validation of a LC-MS/MS method for the determination of viaminate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644497/),%,100.7,231475,DB00755,Tretinoin
,17644497,extraction-efficiency,"The extraction-efficiency at three concentrations was 100.7, 93.6, and 99.7%.",Development and validation of a LC-MS/MS method for the determination of viaminate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644497/),%,93.6,231476,DB00755,Tretinoin
,17644497,extraction-efficiency,"The extraction-efficiency at three concentrations was 100.7, 93.6, and 99.7%.",Development and validation of a LC-MS/MS method for the determination of viaminate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644497/),%,99.7,231477,DB00755,Tretinoin
,2877832,t1/2,"The t1/2 for 4-HPR elimination from the liver was 9.4 hr, from the serum was 12.0 hr (not significantly different from liver), from the mammary gland was 43.6 hr, and from the urinary bladder was 9.3 hr.",N-(4-hydroxyphenyl)-all-trans-retinamide pharmacokinetics in female rats and mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877832/),h,9.4,235428,DB00755,Tretinoin
,2877832,t1/2,"The t1/2 for 4-HPR elimination from the liver was 9.4 hr, from the serum was 12.0 hr (not significantly different from liver), from the mammary gland was 43.6 hr, and from the urinary bladder was 9.3 hr.",N-(4-hydroxyphenyl)-all-trans-retinamide pharmacokinetics in female rats and mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877832/),h,12.0,235429,DB00755,Tretinoin
,2877832,t1/2,"The t1/2 for 4-HPR elimination from the liver was 9.4 hr, from the serum was 12.0 hr (not significantly different from liver), from the mammary gland was 43.6 hr, and from the urinary bladder was 9.3 hr.",N-(4-hydroxyphenyl)-all-trans-retinamide pharmacokinetics in female rats and mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877832/),h,43.6,235430,DB00755,Tretinoin
,2877832,t1/2,"The t1/2 for 4-HPR elimination from the liver was 9.4 hr, from the serum was 12.0 hr (not significantly different from liver), from the mammary gland was 43.6 hr, and from the urinary bladder was 9.3 hr.",N-(4-hydroxyphenyl)-all-trans-retinamide pharmacokinetics in female rats and mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877832/),h,9.3,235431,DB00755,Tretinoin
,3882304,elimination half-lives,Plasma concentrations of isotretinoin following single and multiple doses peak between 2 to 4 hours and exhibit elimination half-lives of 10 to 20 hours.,Clinical pharmacokinetics of the retinoids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3882304/),h,10 to 20,238647,DB00755,Tretinoin
,3882304,elimination half-life,"Pharmacokinetically, the major difference between isotretinoin and etretinate is the much longer elimination half-life (120 days) of etretinate following long term administration.",Clinical pharmacokinetics of the retinoids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3882304/),d,120,238648,DB00755,Tretinoin
,1377120,terminal elimination half-life,"Acitretin is less lipophilic than etretinate, and its lack of sequestration into 'deep' fatty storage sites is reflected in a comparatively short terminal elimination half-life of 50 to 60 hours, compared with 120 days for etretinate.",Acitretin. A review of its pharmacology and therapeutic use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1377120/),h,50 to 60,238657,DB00755,Tretinoin
,1377120,terminal elimination half-life,"Acitretin is less lipophilic than etretinate, and its lack of sequestration into 'deep' fatty storage sites is reflected in a comparatively short terminal elimination half-life of 50 to 60 hours, compared with 120 days for etretinate.",Acitretin. A review of its pharmacology and therapeutic use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1377120/),d,120,238658,DB00755,Tretinoin
,25907597,drug loading efficiency,"The drug loading efficiency of ATRA-PEG500, ATRA-PEG1000, ATRA-PEG2000, and ATRA-PEG5000 was about 38.4, 26.6, 13.1, and 5.68 wt%, respectively.",Critical determinant of intestinal permeability and oral bioavailability of pegylated all trans-retinoic acid prodrug-based nanomicelles: Chain length of poly (ethylene glycol) corona. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25907597/),wt%,38.4,245593,DB00755,Tretinoin
,25907597,drug loading efficiency,"The drug loading efficiency of ATRA-PEG500, ATRA-PEG1000, ATRA-PEG2000, and ATRA-PEG5000 was about 38.4, 26.6, 13.1, and 5.68 wt%, respectively.",Critical determinant of intestinal permeability and oral bioavailability of pegylated all trans-retinoic acid prodrug-based nanomicelles: Chain length of poly (ethylene glycol) corona. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25907597/),wt%,26.6,245594,DB00755,Tretinoin
,25907597,drug loading efficiency,"The drug loading efficiency of ATRA-PEG500, ATRA-PEG1000, ATRA-PEG2000, and ATRA-PEG5000 was about 38.4, 26.6, 13.1, and 5.68 wt%, respectively.",Critical determinant of intestinal permeability and oral bioavailability of pegylated all trans-retinoic acid prodrug-based nanomicelles: Chain length of poly (ethylene glycol) corona. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25907597/),wt%,13.1,245595,DB00755,Tretinoin
,25907597,drug loading efficiency,"The drug loading efficiency of ATRA-PEG500, ATRA-PEG1000, ATRA-PEG2000, and ATRA-PEG5000 was about 38.4, 26.6, 13.1, and 5.68 wt%, respectively.",Critical determinant of intestinal permeability and oral bioavailability of pegylated all trans-retinoic acid prodrug-based nanomicelles: Chain length of poly (ethylene glycol) corona. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25907597/),wt%,5.68,245596,DB00755,Tretinoin
,25907597,half-time,"More importantly, they were all rapidly hydrolyzed into the parent drug in hepatic homogenate, with the half-time values being 0.3-0.4h.",Critical determinant of intestinal permeability and oral bioavailability of pegylated all trans-retinoic acid prodrug-based nanomicelles: Chain length of poly (ethylene glycol) corona. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25907597/),h,0.3-0.4,245597,DB00755,Tretinoin
less,8174117,area under RA concentration over time curve,"Patients were considered to have ""normal"" or ""rapid"" baseline catabolism of RA if their Day 1 area under RA concentration over time curve was greater or less than 300 ng.h/ml, respectively.",Elevated plasma lipid peroxide content correlates with rapid plasma clearance of all-trans-retinoic acid in patients with advanced cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8174117/),[h·ng] / [ml],300,249173,DB00755,Tretinoin
,7923564,AUC,"Following continuous oral treatment, the mean day-28 AUC of all-trans RA was significantly lower than the group mean level on day 1 (504 vs 132 ng h-1 ml-1; P = 0.05).",Modulation of all-trans retinoic acid pharmacokinetics by liarozole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923564/),[ng] / [h·ml],504,251206,DB00755,Tretinoin
,7923564,AUC,"Following continuous oral treatment, the mean day-28 AUC of all-trans RA was significantly lower than the group mean level on day 1 (504 vs 132 ng h-1 ml-1; P = 0.05).",Modulation of all-trans retinoic acid pharmacokinetics by liarozole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923564/),[ng] / [h·ml],132,251207,DB00755,Tretinoin
,7923564,AUC,"This decline in plasma concentrations on day 28 was partially reversed by liarozole, which increased the mean plasma all-trans RA AUC on day 29 to 243 ng h-1 ml-1 (P = 0.004).",Modulation of all-trans retinoic acid pharmacokinetics by liarozole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923564/),[ng] / [h·ml],243,251208,DB00755,Tretinoin
<,7967726,half-lives,RA is much more rapidly cleared from plasma following oral administration; their respective half-lives are < 1 h and 13 h.,Clinical pharmacology of all-trans retinoic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7967726/),h,1,251638,DB00755,Tretinoin
,7967726,half-lives,RA is much more rapidly cleared from plasma following oral administration; their respective half-lives are < 1 h and 13 h.,Clinical pharmacology of all-trans retinoic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7967726/),h,13,251639,DB00755,Tretinoin
,7039821,maximum dose,"All patients received p.o. 13-cis-retinoic acid starting at 0.5 mg/kg/day, escalating over 4 weeks to a maximum dose of 8 mg/kg/day in divided doses.",Pharmacology of 13-cis-retinoic acid in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039821/),[mg] / [d·kg],8,251837,DB00755,Tretinoin
,7039821,peak plasma concentration,"At the maximum drug dose, the mean peak plasma concentration was 4 X 10(-6) M.",Pharmacology of 13-cis-retinoic acid in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039821/),M,4 X 10(-6),251838,DB00755,Tretinoin
below,7039821,trough concentrations,"There was little drug accumulation on this schedule, as trough concentrations between p.o. doses often dropped below 1 X 10(-6) M.",Pharmacology of 13-cis-retinoic acid in humans. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039821/),M,1 X,251839,DB00755,Tretinoin
,2980988,IC50,"In the in vitro assay, only etretin suppressed chondrogenesis and this activity was equivalent to that of all-trans-retinoic acid (IC50 of 12 ng/ml).",Transplacental pharmacokinetics of teratogenic doses of etretinate and other aromatic retinoids in mice. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2980988/),[ng] / [ml],12,254118,DB00755,Tretinoin
,24440824,limit of detection,The method was validated over the linear range of 1.0-5000ng/ml (r(2)=0.999) for both vitamins with a limit of detection of 0.5ng/ml.,Development of a validated UPLC method for simultaneous estimation of both free and entrapped (in solid lipid nanoparticles) all-trans retinoic acid and cholecalciferol (vitamin D3) and its pharmacokinetic applicability in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440824/),[ng] / [ml],0.5,254735,DB00755,Tretinoin
,24440824,flow rate,"Chromatographic separation was achieved using liquid-liquid extraction (LLE) on an Acquity BEH RP 18 column (2.1mm×50mm, I.D. 1.7μm), with mobile phase comprising of acetonitrile:methanol:water (90:8:2, v/v/v), at a flow rate of 0.20ml/min and a total run time of 5min.",Development of a validated UPLC method for simultaneous estimation of both free and entrapped (in solid lipid nanoparticles) all-trans retinoic acid and cholecalciferol (vitamin D3) and its pharmacokinetic applicability in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440824/),[ml] / [min],0.20,254736,DB00755,Tretinoin
,24440824,total run time,"Chromatographic separation was achieved using liquid-liquid extraction (LLE) on an Acquity BEH RP 18 column (2.1mm×50mm, I.D. 1.7μm), with mobile phase comprising of acetonitrile:methanol:water (90:8:2, v/v/v), at a flow rate of 0.20ml/min and a total run time of 5min.",Development of a validated UPLC method for simultaneous estimation of both free and entrapped (in solid lipid nanoparticles) all-trans retinoic acid and cholecalciferol (vitamin D3) and its pharmacokinetic applicability in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440824/),min,5,254737,DB00755,Tretinoin
≥,24440824,recovery,High recovery of ≥96.0% for ATRA and ≥87.80% for vitamin D3 was achieved.,Development of a validated UPLC method for simultaneous estimation of both free and entrapped (in solid lipid nanoparticles) all-trans retinoic acid and cholecalciferol (vitamin D3) and its pharmacokinetic applicability in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440824/),%,96.0,254738,DB00755,Tretinoin
≥,24440824,recovery,High recovery of ≥96.0% for ATRA and ≥87.80% for vitamin D3 was achieved.,Development of a validated UPLC method for simultaneous estimation of both free and entrapped (in solid lipid nanoparticles) all-trans retinoic acid and cholecalciferol (vitamin D3) and its pharmacokinetic applicability in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440824/),%,87.80,254739,DB00755,Tretinoin
,8129749,IC50,"Formation of both hydroxy-keto derivatives was suppressed by the imidazole-containing P450 inhibitor liarozole fumarate (IC50, 1.3 microM).",Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8129749/),μM,1.3,255796,DB00755,Tretinoin
,8129749,half-life,"In vitro, an i.v. injection of 4-keto-RA (20 micrograms) into rats was followed by rapid disappearance of the retinoid from plasma with a half-life of 7 min.",Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8129749/),min,7,255797,DB00755,Tretinoin
,8129749,plasma half-life,"Pretreatment with liarozole fumarate (40 mg/kg, -60 min) reduced the elimination rate of 4-keto-RA: it prolonged the plasma half-life of the retinoid to 12 min, without affecting its distribution volume.",Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8129749/),min,12,255798,DB00755,Tretinoin
,17879972,IC(50),The IC(50) in ATRA of the ATRA emulsion for the Caco-2 carcinoma cells was 3.8 microg/mL lower than 6 microg/mL of the ATRA solution.,Evaluation of the pharmacokinetics of all-trans-retinoic acid (ATRA) in Wistar rats after intravenous administration of ATRA loaded into tributyrin submicron emulsion and its cellular activity on caco-2 and HepG2 cell lines. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879972/),[μg] / [ml],3.8,256703,DB00755,Tretinoin
,17879972,IC(50),The IC(50) in ATRA of the ATRA emulsion for the Caco-2 carcinoma cells was 3.8 microg/mL lower than 6 microg/mL of the ATRA solution.,Evaluation of the pharmacokinetics of all-trans-retinoic acid (ATRA) in Wistar rats after intravenous administration of ATRA loaded into tributyrin submicron emulsion and its cellular activity on caco-2 and HepG2 cell lines. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879972/),[μg] / [ml],6,256704,DB00755,Tretinoin
,17879972,IC(50),"The IC(50) of the emulsion for the HepG2 carcinoma cells was 2.8 microg/mL, while IC(50) was not achieved with the ATRA solution over the test concentration range.",Evaluation of the pharmacokinetics of all-trans-retinoic acid (ATRA) in Wistar rats after intravenous administration of ATRA loaded into tributyrin submicron emulsion and its cellular activity on caco-2 and HepG2 cell lines. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879972/),[μg] / [ml],2.8,256705,DB00755,Tretinoin
,2150173,cis/trans ratio,"When etretinate and acitretin dissolved in ethanol were irradiated with UVB (280-320 nm; 10-336 mJ/cm2) or UVA (320-400 nm; 1-5 J/cm2), extensive and reproducible cis-isomerizations occurred at the 13-position (cis/trans ratio approximately 1.6 in all experiments) but there was no progressive photodegradation of the molecules.",UV-induced isomerization of oral retinoids in vitro and in vivo in hairless mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150173/),,1.6,257152,DB00755,Tretinoin
,6575917,half-life,The harmonic mean half-life for the elimination of isotretinoin by the cystic acne patients was approximately 10 h after the initial dose and did not change significantly following 25 days of 40 mg b.i.d. dosing.,Pharmacokinetics of isotretinoin during repetitive dosing to patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6575917/),h,10,263127,DB00755,Tretinoin
,6575917,elimination half-life,The harmonic mean elimination half-life in the patients with various disorders of keratinization was about 16 h.,Pharmacokinetics of isotretinoin during repetitive dosing to patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6575917/),h,16,263128,DB00755,Tretinoin
,11060348,turnover times (1/k(el)),"The turnover times (1/k(el)) for beta-carotene and retinol were 58 and 302 days, respectively.","Long-term kinetic study of beta-carotene, using accelerator mass spectrometry in an adult volunteer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11060348/),d,58,263436,DB00755,Tretinoin
,11060348,turnover times (1/k(el)),"The turnover times (1/k(el)) for beta-carotene and retinol were 58 and 302 days, respectively.","Long-term kinetic study of beta-carotene, using accelerator mass spectrometry in an adult volunteer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11060348/),d,302,263437,DB00755,Tretinoin
,8410127,half-lives (t1/2 beta),"After discontinuation of 5-year treatment, 4HPR and 4MPR half-lives (t1/2 beta) were 27 and 54 hours, respectively, similar to those reported after 28 daily treatments.",Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410127/),h,27,265263,DB00755,Tretinoin
,8410127,half-lives (t1/2 beta),"After discontinuation of 5-year treatment, 4HPR and 4MPR half-lives (t1/2 beta) were 27 and 54 hours, respectively, similar to those reported after 28 daily treatments.",Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410127/),h,54,265264,DB00755,Tretinoin
,7895612,apparent half-life,"Following 9-cis-RA administration, plasma levels of 9-cis-RA reached their maximum within 40-60 min and then declined in a monoexponential manner with an apparent half-life of 64 +/- 32 min.","Identification of 9,13-dicis-retinoic acid as a major plasma metabolite of 9-cis-retinoic acid and limited transfer of 9-cis-retinoic acid and 9,13-dicis-retinoic acid to the mouse and rat embryos. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7895612/),min,64,265268,DB00755,Tretinoin
,1495103,first-order (terminal) half-life,"The first-order (terminal) half-life for all-trans-RA averaged 19 minutes, and the mean clearances were 77, 52, and 59 mL/min for the 20-, 50-, and 100-mg/m2 dose groups, respectively.",Dose-dependent pharmacokinetics of all-trans-retinoic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495103/),min,19,265404,DB00755,Tretinoin
,1495103,clearances,"The first-order (terminal) half-life for all-trans-RA averaged 19 minutes, and the mean clearances were 77, 52, and 59 mL/min for the 20-, 50-, and 100-mg/m2 dose groups, respectively.",Dose-dependent pharmacokinetics of all-trans-retinoic acid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495103/),[ml] / [min],77,265405,DB00755,Tretinoin
,1495103,clearances,"The first-order (terminal) half-life for all-trans-RA averaged 19 minutes, and the mean clearances were 77, 52, and 59 mL/min for the 20-, 50-, and 100-mg/m2 dose groups, respectively.",Dose-dependent pharmacokinetics of all-trans-retinoic acid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495103/),[ml] / [min],52,265406,DB00755,Tretinoin
,1495103,clearances,"The first-order (terminal) half-life for all-trans-RA averaged 19 minutes, and the mean clearances were 77, 52, and 59 mL/min for the 20-, 50-, and 100-mg/m2 dose groups, respectively.",Dose-dependent pharmacokinetics of all-trans-retinoic acid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495103/),[ml] / [min],59,265407,DB00755,Tretinoin
,1495103,Michaelis constant (Km),The mean +/- SD Michaelis constant (Km) for the capacity-limited process was 3.2 +/- 1.9 microM.,Dose-dependent pharmacokinetics of all-trans-retinoic acid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495103/),μM,3.2,265408,DB00755,Tretinoin
,8868029,overall excretion,"During a 7-day period, the overall excretion of radioactivity derived from RA and RAG in the feces and urine were similar, e.g. 17 and 12%, respectively.","Percutaneous absorption, excretion and metabolism of all-trans-retinoyl beta-glucuronide and of all-trans-retinoic acid in the rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8868029/),%,17,270668,DB00755,Tretinoin
,8868029,overall excretion,"During a 7-day period, the overall excretion of radioactivity derived from RA and RAG in the feces and urine were similar, e.g. 17 and 12%, respectively.","Percutaneous absorption, excretion and metabolism of all-trans-retinoyl beta-glucuronide and of all-trans-retinoic acid in the rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8868029/),%,12,270669,DB00755,Tretinoin
,9363862,area under the concentration-time curve (AUC),"Following 30-mg/m2 doses, the ATRA area under the concentration-time curve (AUC) decreased from 96 +/- 14 micromol/L/min on day 1 to 26 +/- 24 micromol/L/min by day 3 of drug administration, but on day 1 of the fourth consecutive week of therapy, the AUC averaged 110 +/- 16 micromol/L/min.",Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9363862/),[μM] / [l·min],96,270798,DB00755,Tretinoin
,9363862,area under the concentration-time curve (AUC),"Following 30-mg/m2 doses, the ATRA area under the concentration-time curve (AUC) decreased from 96 +/- 14 micromol/L/min on day 1 to 26 +/- 24 micromol/L/min by day 3 of drug administration, but on day 1 of the fourth consecutive week of therapy, the AUC averaged 110 +/- 16 micromol/L/min.",Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9363862/),[μM] / [l·min],26,270799,DB00755,Tretinoin
,9363862,AUC,"Following 30-mg/m2 doses, the ATRA area under the concentration-time curve (AUC) decreased from 96 +/- 14 micromol/L/min on day 1 to 26 +/- 24 micromol/L/min by day 3 of drug administration, but on day 1 of the fourth consecutive week of therapy, the AUC averaged 110 +/- 16 micromol/L/min.",Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9363862/),[μM] / [l·min],110,270800,DB00755,Tretinoin
,20606092,MTD,"In patients with solid tumors, the MTD was 230 mg/m(2)/d with dose-limiting neutropenia, thrombocytopenia, and hypokalemia at 300 mg/m(2)/d.",Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20606092/),[mg] / [m(2],230,273985,DB00755,Tretinoin
,20606092,area under the concentration-time curves,"Wide interpatient variability was noted in vorinostat disposition, with area under the concentration-time curves at 230 mg/m(2)/d for the capsule (range, 1,415 to 9,291 ng/mL x hr) and oral suspension (range, 1,186 to 4,780 ng/mL x hr).",Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20606092/),[ng] / [h·ml],230,273986,DB00755,Tretinoin
,20606092,area under the concentration-time curves,"Wide interpatient variability was noted in vorinostat disposition, with area under the concentration-time curves at 230 mg/m(2)/d for the capsule (range, 1,415 to 9,291 ng/mL x hr) and oral suspension (range, 1,186 to 4,780 ng/mL x hr).",Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20606092/),[ng] / [h·ml],"1,415 to 9,291",273987,DB00755,Tretinoin
,20606092,area under the concentration-time curves,"Wide interpatient variability was noted in vorinostat disposition, with area under the concentration-time curves at 230 mg/m(2)/d for the capsule (range, 1,415 to 9,291 ng/mL x hr) and oral suspension (range, 1,186 to 4,780 ng/mL x hr).",Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20606092/),[ng] / [h·ml],"1,186 to 4,780",273988,DB00755,Tretinoin
